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Abstract 
1-Deoxy-sphingolipds (dSL) are atypical and neurotoxic sphingolipids which are 
formed by the enzyme serine palmitoyltransferase (SPT) due to a promiscuous use of 
L-alanine over its canonical substrate L-serine. Pathologically elevated dSL levels are 
a hallmark for the rare hereditary sensory neuropathy type I (HSAN I) - which is 
caused by several missense mutations in SPT. Significantly elevated dSL levels were 
also found in patients with Metabolic Syndrome (MetS) or diabetes type 2 (T2DM) as 
demonstrated in various clinical studies. The mechanisms which underlie this 
increased dSL formation in metabolic disorders is not understood.  
Here, we report two novel HSAN I causing mutations in the SPTLC2 subunit of SPT. 
The A182P variant was found in two members of a single family and the S384F 
variant in members of two unrelated families. We showed detailed clinical and 
neurological assessments, confirming the association of these mutations with HSAN I. 
All affected patients had elevated plasma dSL levels that were comparable to patients 
with other previously described HSAN I mutations, further supporting the concept 
that elevated plasma dSLs are a hallmark for HSAN I. The ectopic expression of the 
A182P and S384F mutants in HEK293 cells increased dSL formation.  
Interestingly, the S384F mutation resides at a putative phosphorylation site of 
SPTLC2. Therefore we investigated the influence of this site on SPT activity and 
substrate specificity by creating a set of constitutively phosphorylated and non-
phosphorylated SPTLC2 mutants. We demonstrated that the phosphorylation 
mimicking mutant S384D leads to increased dSL generation in isolated proteins and 
in intact cells. This was not observed for the S384A mutant where the phospho-site 
was knocked-out. Increasing L-alanine concentrations in the culture media elevated 
dSL generation in cells expressing the SPTLC2 S384D mutant but not in cells 
expressing wt SPTLC2. We therefore suggest that phosphorylation of S384 can act as 
a molecular switch to shift between the two amino acid substrates. A molecular 
mechanism to regulate the dSL formation also argues for a physiological function of 
these lipids.  
Comparing several cell lines, we found high endogenous dSL levels in RAW 
macrophages but not in monocyte cell lines like THP or HL60. We showed that THP1 
monocytes generate dSLs during their PMA induced differentiation into macrophages 
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and confirmed this effect in primary human monocytes. The dSL formation correlated 
with changes of intracellular L-alanine levels. Whether dSL formation has a 
physiological relevance during macrophage maturation is not clear yet.  
In conclusion we propose that dSL generation in the SPT wt enzyme is partly 
depending on intracellular alanine levels but needs additional factors to switch 
between the use of L-serine and L-alanine as substrates. This substrate shift might be 
regulated by a phosphorylation of SPTLC2 at position S384.  
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Zusammenfassung 
 
Deoxy-Sphingolipide (DSL) sind untypische neurotoxische Sphingolipide, die von 
dem Enzym Serine Palmitoyltransferase (SPT) aufgrund einer Substratverschiebung 
von L-Serin zu L-Alanin gebildet werden. Pathologisch erhöhte Deoxy-sphingolipid-
Blutwerte sind ein Kennzeichen der seltenen vererbbaren peripheren Neuropathie 
HSAN I, die durch unterschiedliche Mutationen in den beiden Untereinheiten der SPT 
verursacht wird. Wie in vielen klinischen Studien gezeigt wurde, sind DSL-Blutwerte 
ebenfalls signifikant erhöht in Patienten, die an dem metabolischen Syndrom oder 
Diabetes Typ 2 leiden. Es ist nicht bekannt welche Mechanismen zu den erhöhten 
DSL Werten in diesen metabolischen Stoffwechselstörungen beitragen. Hier berichten 
wir von zwei neuen Mutationen in der SPTLC2 Untereinheit, welche HSAN I 
verursachen. Die A182P Mutation wurde in zwei Mitgliedern einer Familie und die 
S384F Variante in Mitgliedern von zwei unterschiedlichen Familien gefunden. Durch 
klinische und neurologische Untersuchungen konnten wir einen Zusammenhang 
zwischen HSAN I und den, in den Patienten gefunden Mutationen bestätigen. Alle 
betroffenen Patienten zeigten erhöhte DSL-Blutwerte, die vergleichbar sind mit DSL 
Blutwerten bei bereits charakterisierten HSAN I Mutationen. Dies unterstreicht 
weiterhin den Zusammenhang von erhöhten DSL-Blutwerten mit dem HSAN I 
Phenotyp. Die vermehrte Bildung von DSL konnte auch in HEK293 Zellen gezeigt 
werden, welche die Mutationen im SPTLC2 Gen trugen. 
Beim Versuch, unbekannte Phosphorylierungsstellen im Hela Proteom zu 
identifizieren, wurden zwei potentielle Phosphorylierungssstellen in der SPTLC2 
Unterheit identifiziert. Diese gaben jedoch keinen direkten Hinweis auf eine 
abgeänderte Funktion der SPTLC2 Untereinheit. Eine der beiden potentiellen 
Phosphorylierungsstellen befindet sich an der gleichen Stelle wie die hier 
charakterisierte neu entdeckte HSAN I-S384F Mutation. 
Wir untersuchten daraufhin den Einfluss dieser Phosphorylierungsstelle auf die 
Aktivität und Substratspezifität der SPT indem wir eine permanente Phosphorylierung 
(S384D) sowie De-Phosphorylierung (S384A) and dieser Stelle simulierten.  
Untersuchung der SPT Aktivität in isolierten Proteinen und in intakten Zellen ergab, 
dass eine simulierte Phosphorylierung (S384D) zu einer erhöhten DSL Bildung führt. 
Die Mutante mit permanent de-phosphorylierter SPT (S384A) zeigte keine erhöhte 
DSL Synthese. Ansteigende L-Alanin Konzentrationen, die dem Kulturmedium 
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zugegeben wurden, führten zu einer erhöhten DSL Bildung in HEK Zellen mit 
simulierter Phosphorylierung (S384D), allerdings nicht in HEK Wildtyp Zellen. 
Basierend auf diesen Ergebnissen, schlagen wir ein Model vor, in dem die 
Phosphorylierung an der Stelle S384 in der SPTLC2 Untereinheit, die Funktion eines 
molekularen Schalters besitzt, der es erlaubt, zwischen den beiden Substraten L-
Alanin und L-Serin zu wechseln. Das Vorhandensein eines solchen molekularen 
Mechanismus, zur Regulierung der DSL Bildung, lässt darauf schliessen, dass diese 
Lipide eine physiologische Relevanz haben. Der Vergleich verschiedener Zelllinien 
ergab, dass RAW Makrophagen nicht aber die Monozyten Zelllinien (THP1, HL60) 
hohe endogene Mengen an DLS aufweisen. Wir konnten zeigen, dass während einer 
PMA stimulierten Differenzierung von THP1 Monozyten zu Makrophagen, sowie in 
primären humanen Monozyten, die Synthese von DSL ansteigt. Hierbei korrelierte der 
Anstieg an DSL mit den intrazellulären L-Alanin Konzentrationen. Eine 
physiologische Relevanz von DSL während der Differenzierung gilt es weiter 
aufzuklären. Zusammenfassend schlagen wir ein Model vor, in dem die DSL Bildung 
durch die wildtyp SPT teilweise von der intrazellulären L-Alanin Konzentration 
abhängt, aber zusätzlich auf Faktoren angewiesen ist, die den Substratwechsel 
zwischen L-Serin und L-Alanin regulieren. Dieser Substratwechsel könnte durch eine 
Phosphorylierung von Serin an der Stelle 384 in der SPTLC2 reguliert werden.
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General Introduction 
I. Sphingolipid de novo synthesis and degradation 
pathway 
Serine palmitoyltransferase (SPT) catalyzes the first step in the sphingolipid de novo 
synthesis1 by metabolizing L-serine together with palmitoyl-CoA. The product 3-
keto-sphinganine is rapidly reduced to sphinganine (SA) by the 3-keto-sphinganine 
reductase. Subsequently sphinganine is N-acylated to dihydro-ceramide, a reaction 
that is catalyzed by one of several isoforms of ceramide synthases2. Next, a desaturase 
introduces a trans double bond between the C4 and C5 in the sphingoid base 
backbone which results in ceramides3, 4. The 4,5 double-bond is only inserted into the 
dihydro-ceramide but not into SA directly5. The ceramides serve as a hub for the 
generation of complex sphingolipids, like glycosphingolipids, ceramide-1-phosphate 
and sphingomyelin6-8. Despite being metabolized to complex sphingolipids, ceramide 
can also be de-acylated to form sphingosine (SO) - a reaction that is catalyzed by 
various ceramidases9 (all steps are illustrated in Figure 1).  
 
Sphingolipid degradation 
During the degradation of complex sphingolipids, mostly lysosomal enzymes 
(sphingomyelinases, glucocerebrosidases, ceramidases) are involved which leads 
eventually to the formation of ceramide and SO. In the salvage pathway SO can be re-
acylated by CerS to form again ceramides10. It was suggested that ceramides that are 
generated through the salvage pathway cause different biological responses (growth 
arrest11, apoptosis12, cellular signaling13 and trafficking14) compared to de novo 
generated ceramides. At the end of the sphingolipid degradation process, SO is 
phosphorylated to SO-1-phosphate (S1P) by SO-1-kinase. S1P can again be 
dephosphorylated by certain lipid phosphatases or irreversibly degraded by 
sphingosine-1-phosphate-lyase, a PLP-dependent enzyme that catalyzes the cleavage 
to phospho-ethanolamine and trans-hexadecenal15 (Figure 1).  Trans-hexadecenal was 
shown to cause cytoskeletal reorganization, detachment and apoptosis16. Moreover it 
has been shown to form adducts with DNA thereby potentially causing cancer17.  
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FIGURE 1: Sphingolipid de novo synthesis and degradation pathway  
General Introduction 
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Sphingolipid de novo synthesis and degradation pathways are spatially separated 
The steps of the sphingolipid de novo synthesis that lead to the formation of ceramide 
take place at the cytosolic leaflet of the ER.  Ceramide, either bound to the CER 
transfer protein (CERT) or integrated into vesicles, is transported to the Golgi where it 
is converted to glycosphingolipids and sphingomyelin that are transported to the 
plasma-membrane by vesicular transport1, 10. Two sphingomyelinases were reported, 
one located in the Golgi and one at the plasma-membrane (PM)18. The 
phosphorylation of ceramide was reported to happen at the PM, Golgi and in the 
cytoplasm19, 20. De-acylation of ceramide by ceramidases results in the release of 
sphingosine and a free fatty acid which can occur at neutral, alkaline or acidic pH. 
Neutral ceramidase is located at the PM21, acid ceramidase is lysosomal22 and alkaline 
ceramidase is located at the ER/Golgi complex23 (all illustrated in Figure 2). 
 
 
FIGURE 2: Compartmentalization of the sphingolipid pathway 
(Picture taken from Hannun and Obeid et al.24) 
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II. Key enzymes involved in ceramide de novo 
synthesis 
1. Serine palmitoyltransferase (SPT) 
SPT mRNA expression and enzymatic activity were shown to be influenced by many 
factors including UV radiation25, endotoxins26-28, cytokines27, phorbol-ester29, 
daunorubicin30, magnesium defiency31, nicotinamide32, hypoxia33 and others . Many 
of these stimuli are inflammatory, toxic or induce some other forms of cell stress. 
Furthermore, SPT activity was shown to be highly dependent on the supply of its 
substrates, L-serine and palmitate34. Other stimuli like retinoic acid35, cannabinoids36 
and etoposide37 have been reported to influence SPT activity without changing 
mRNA or protein levels which argues for posttranslational regulation. Several 
microRNAs were reported to negatively regulate SPTLC1 (miR-137/-181c) and 
SPTLC2 (miR-9/-29a/b-1) expression levels38. The loss of these micro RNAs 
increased SPT activity which resulted in higher ceramide levels and increased 
amyloid β formation in sporadic Alzheimer`s disease. Furthermore, two 
phosphorylation sites (S384, Y387) in the SPTLC2 subunit were found in an unbiased 
global proteomic approach to analyze the phospho-proteom in HeLa cells after EGF 
stimulation. The observed phosphorylation of SPTLC2 was independent of the EGF 
stimulus and the reported sequence motif was linked to casein kinase 139. The effect 
on SPT activity or the context in which the phosphorylation occurs has not been 
investigated and is addressed in this report.  
 
2. Ceramide synthases (CerS) 
Ceramide synthases are catalyzing the N-acylation of sphinganine to form dihydo-
ceramides.  Six CerS isoforms are known40 and expressed in a unique tissue 
distribution. The individual CerS isoforms show a special preference for a certain 
fatty-acid - CoA substrate. The N-acylation of a selection of various fatty acids results 
in a broad variety of formed ceramide species as reviewed by Hannun41. In detail, 
CerS1 uses mostly C18-CoA42, CerS4 C18- and C20-CoAs43, CerS5 and CerS6 
mainly C16-CoAs43, 44 and CerS3 is most specific for very long chain acyl-CoAs like 
C26 and higher ones45. CerS2 in contrast has a rather broad specificity and 
metabolizes typically C22 to C24-CoAs46.  Not much is known about the regulation 
and interaction of the various CerS isoforms. Ectopic expression of CerS1 and CerS5 
General Introduction 
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have been shown to sensitize cells to various drugs whereby CerS1 showed the 
broadest spectrum for the tested drugs (cisplatin, doxorubicin, carboplatin, 
vincristine)47. CerS1 protein levels were shown to be down-regulated due to stress 
stimuli like cisplatin or UV light. This turnover is regulated via phosphorylation by 
the opposing functions of p38MAP kinase (positive regulation) and PKC (negative 
regulation) where an activated PKC was associated with increased phosphorylation of 
CerS1 and reduced turnover48. Phosphorylation sites were also found in CerS539 and 
CerS2 39, 49-52 whereas Cers2 was also shown to be glycosylated53. No functional 
consequence has been linked to these regulatory sites so far. A recent report described 
the modulation of CerS activity by dimer formation54. Ceramide synthase activity was 
shown to increase by dimerization of certain CerS isoforms, enabling the cell to 
respond rapidly to changing physiological conditions. 
 
3. Dihydro-ceramide desaturase (DES) 
Two dihydro-ceramide desaturases have been reported - DES1 and DES2. DES1 was 
shown to have high dihydro-ceramide Δ4-desaturase and very low C-4 hydroxylase 
activities, whereas the ortholog DES2 exhibits a bifunctional sphingolipid C-4 
hydroxylase and Δ 4-desaturase activity55. DES1 expression is ubiquitous whereas 
DES2 is most strongly expressed in skin, intestines and kidney, thereby leading to the 
higher levels of phyto-sphingolipids in these tissues56. Recently, DES1 was also 
identified as a retinol isomerase in a proposed alternative visual cycle for regenerating 
opsins in daylight57. As DES1 is the only known source of 9-cis-retinoic acid in 
vertebrates, the same group suggested that DES1 is an isomerase-2 which plays a role 
in other, nonvisual processes that are linked to 9-cis-retinoic acid like cell growth, 
differentiation or malignant transformation. The activity of DES1 increases upon 
attachment of myristate to the N-terminal glycine of the eukaryotic enzyme58, 59. 
Furthermore, N-myristoylation was shown to influence the cellular localization of 
DES1, targeting the enzyme to mitochondria where, due to the higher DES activity, 
increased levels of ceramides lead to apoptosis59. Besides, the length of the N-acyl 
chains influenced DES 1 activity as longer chains were associated with a lower in 
vitro DES 1 activity in liver microsomes5. As an exception it was shown that C14 is a 
better substrate over C18, C10, C6 or C260. Moreover, DES1 was shown to be 
inhibited by increased ROS species61 as well as by changes in the cellular redox state 
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(like treatment with antioxidants62) that was monitored via the cellular levels of 
thiols5. Both events were associated with increased dihydro-ceramide levels without 
affecting ceramide levels. Furthermore, hypoxia directly and reversibly inhibited 
dihydro-ceramide desaturase in a manner that was independent of hypoxia inducible 
factor (HIF1a) activation63. DES1 activity was found to be decreased in confluent cell 
layers compared to cells at low-density. Specifically, DES1 activity in cells at low-
density could be decreased by adding conditioned media from confluent cultures and 
also by adding a reducing agent like DTT or L-cysteine64 which confirms the role of 
free thiols as inhibitors of DES1. 
 
III. Characterization of mammalian SPT 
SPT belongs to the family of α-oxoamine synthases (POAS) 65, 66 which in addition to 
SPT includes three other members - the 8-amino-7-oxononanoate synthase (AONS, 
biotin synthesis)67, 68, 5-aminolevulinate synthase (ALAS, heme biosynthesis)69, and 
2-amino-oxobutyrate CoA ligase (KBL, threonine degradation)70. They all catalyse a 
pyridoxal-5-phosphate (PLP) -dependent condensation of an amino acid and an acyl- 
CoA. All members of the POAS family, except the mammalian SPT, are soluble 
homodimers with two active sites which are positioned at the monomer-monomer 
interface. The x-ray structure of the mammalian SPT is not re-solved yet but the 
structure for the prokaryotic SPT was re-solved from two sphingolipid generating 
bacteria, Sphingomonas paucimobilis and Sphingobacterium multivorum71, 72. In 
contrast to the mammalian SPT which is a membrane bound heteromer, the 
prokaryotic form is a homodimer - either soluble (S. paucimobilis) or loosely attached 
to the inner cell membrane (S. multivorum)73. All POAS members contain a conserved 
PLP binding motif (T[FL][GTS]K[SAG][FLV]G) that stretches around the lysine 
residue which forms a Schiff’s base together with PLP 1.  
 
SPT subunits and complex composition 
The mammalian SPT consists of three subunits SPTLC1 (Swiss-prot: O15269), 
SPTLC2 (Swiss-prot: O15270) and SPTLC3 (Swiss-prot: Q9NUV7)1,74,75. All three 
isoforms contain a putative transmembrane domain, but only SPTLC2 and SPTLC3 
contain a PLP-binding motif characterizing them as the catalytically active subunits1, 
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76. SPTLC2 and SPTLC3 show significant sequence similarities (approximately 70%) 
whereas SPTLC1 shows a mutual similarity of approximately 20% to SPTLC2 and 
SPTLC374. The SPTLC1 and SPTLC2 subunits are ubiquitously expressed whereas 
SPTLC3 expression is restricted to certain tissue like placenta, liver and skin75. The 
structural composition of the active SPT enzyme is not completely understood. At 
least a heterodimer between SPTLC1 and SPTLC2 or SPTLC1 and SPTLC3 is 
needed for enzymatic activity1, 77. Results of biochemical analysis suggest that SPT is 
a heteromeric enzyme with a functional molecular weight of 460-480kD.  This 
indicates that SPT is organized as a higher-order, probably octameric complex which 
can be composed of all three subunits77. The stoichiometry between SPTLC2 and 
SPTLC3 within the complex probably depends on their relative expression levels. The 
proposed SPT dimer and higher organized complex is shown in Figure 3.   
 
A:      B: 
        
FIGURE 3: Proposed structure of the mammalian SPT complex77 
A: Functional heterodimer composed of SPTLC1 with either SPTLC2 or SPTLC3 
B: Proposed organization of functional units in a multi-subunit complex 
 
Functionally it was shown that the carbon chain profile of the sphingoid bases in cells 
and tissue is defined by the relative expression of SPTLC2 and SPTLC3 subunit. 
Whereas SPTLC2 has a relatively defined specificity for palmitoyl (C16) CoA 
SPTLC3 is metabolizing a rather broad spectrum of acyl-CoAs in the range between 
C14 and C18. In SPTLC3 rich tissues like placenta and trophoblast-derived cell lines 
(JEG 3, JAR) but also in SPTLC3 transfected HEK cells, SPTLC3 expression levels 
correlated closely with the cellular levels of C16 sphingoid bases76. The biophysical 
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properties and physiological relevance of sphingoid bases with different chain lengths 
was not investigated in detail yet. However, it is reasonable to assume that differences 
in the biophysical properties like a lower hydrophobicity, shorter length, and altered 
lipid-lipid interaction will have some impact on various cellular processes like 
vesicular trafficking, ER-stress, membrane dynamics or the formation of stable 
membrane domains (“rafts”)78. It should be noted that sphingoid bases with a C16 and 
C14 carbon chain are the most abundant sphingoid bases in insects79. Also about 10-
15% of the sphingolipidome in human plasma consists of sphingoid bases with a 
carbon chain length other than C1880.  
 
SPT splice variants 
In gene databases alternative splice-forms of SPT are postulated. Two SPTLC1 
transcripts (Swiss-prot: O15269-1; -2) correlating to 53 and 16 kDa as well as two 
SPTLC3 variants with a putative size of 62 and 19.7kDa (Swiss-prot: Q9NUV7-1;-2) 
can be found. An additional SPTLC1 isoform was described by Wei et al. Here the 
first 32 nucleotides from exon 15 are missing which causes a frame-shift and skipping 
of the original stop codon. This results in a longer transcript (57kD - referred to 
SPTLC1L) which could also be detected on protein level81. However, a systematic 
database screen, revealed additional splice variants for SPTLC1 and SPTLC2. One 
additional variant was found for SPTLC1 which contained the first 143 amino acids 
of the N-terminal part (hSPTLC1-N143).  For SPTLC2 three splice variants were 
identified; hSPTLC2-N162, containing the first 162 N-terminal amino acids, 
hSTPLC2-N204, comprising the first 204 N-terminal amino acids and hSPTLC2-
C293, exhibiting the last 293 amino acids of the C-terminal end including the PLP 
binding motif (Figure 4). 
The mRNA transcripts of these variants were expressed in a tissue specific manner 
and were also detected on protein level. However, overexpression of these variants in 
HEK293 cells had no obvious effect on SPT activity, sphingolipid profile or cell 
growth (unpublished data). 
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FIGURE 4: Schematic illustration of proposed SPT isoforms  
SPTLC1L described by Wei81, the three SPTLC2 splice variants (-N162, C293 and N204) 
were found by expressed sequence tag (EST) searches (unpublished data). 
 
Orm proteins negatively regulate yeast and mammalian SPT 
In addition to the three main subunits (SPTLC1-3) other proteins have been reported 
to interact with SPT. The ORM proteins have been shown to regulate SPT activity by 
a metabolic feedback mechanism to maintain sphingolipid homeostasis and to prevent 
the harmful overproduction of ceramides by the de novo synthesis pathway. The 
ORM family consists of two members in yeast (Orm1/2) and three members in 
mammalians (ORMDL1/2/3)82.  
It has been shown in yeast that non-phosphorylated Orm1/2 proteins bind to SPT 
thereby inhibiting its activity and sphingolipid de novo synthesis. If cells are in need 
of sphingolipid de novo formation, Orm proteins get successively phosphorylated and 
dissociate from the SPT complex thereby releasing SPT activity. In yeast, 
phosphorylation of the Orm1/2 proteins is catalyzed by Ypk1 via a TORC2 –
dependent pathway 83. When sphingolipid levels are restored, Orm1/2 proteins are de-
phosphorylated by Sac1 phosphatase which leads to  inhibition of SPT activity84. In 
yeast, a multisubunit complex called “SPOTS” was described that consists of 
Lcb1/Lcb2/Tsc3, Orm1/2 and the phosphoinositide phosphatase Sac184, 85.  
The role of the ORM proteins in yeast was put forward by Sun et al.86 who 
demonstrated that Orm phosphorylation is triggered by the heat stress induced 
depletion of sphingolipids, via the Pkh-Ypk pathway. Upon heat stress the Pkh-
General Introduction 
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TORC2-Ypk cascade is quickly activated which leads to rapid phosphorylation of the 
Orm proteins and the activation of sphingolipid de novo synthesis. The accumulation 
of intermediate metabolites of the sphingolipid synthesis pathway promotes a 
metabolic feedback mechanism that leads to de-phosphorylation of Orm proteins 
which in turn inhibits SPT. The de-phosphorylation of the ORM proteins was shown 
to be either due to inhibition of the Pkh-Ypk kinase 87 or by activation of Cdc55-PPA 
phosphatase 86.  The activation of Ypk1 by heat stress was proposed to be mediated 
via Slm1/2 that act as a sensor for the rigidity and dynamics of the plasma membrane. 
The release of Pkh kinase and Slm1/2 from eisosomes, activate TORC2 and trigger 
Ypk activation86. Since in yeast ORM2 is 10-fold higher expressed than Orm1, the 
authors speculated that this mechanism is primarily mediated by ORM2.  
However, Liu and colleagues88 proposed that Orm1 and Orm2 regulate sphingolipid 
synthesis by different mechanisms. They reported that Orm1 phosphorylation is 
increased upon supplementation of rapamycin to the growth media whereas Orm2 
phosphorylation was not affected. Moreover, they found Orm1 phosphorylation partly 
mediated by protein kinase Npr1 and to be dependent on the Tap42-Sit4 protein 
phosphatase complex that acts downstream of TORC1. Thereby, the cell is able to 
respond to environmental stimuli like nutritional signals. Furthermore, they described 
a compensatory link between the two Orm proteins: Orm1 phosphorylation is altered 
in response to a loss or increased Orm2 expression. They demonstrated that Orm1 
phosphorylation is increased (to activate SPT) when Orm2 is overexpressed, and that 
Orm1 is dephosphorylated (to inhibit SPT) when Orm2 is absent. This could be a 
compensatory response to balance SPT activity since Orm2 levels increase upon ER 
stress 85 whereas Orm1 is phosphorylated upon ER stress 88. In addition an interaction 
of Orm1 and Orm2 with the ceramide synthase subunit, Lac1 was reported which was 
independent from the phosphorylation status of both Orm proteins88.  
Besides their role in regulating sphingolipid synthesis, overexpression of Orm2 (and 
to a lower extent of Orm1) was associated with resistance to high iron concentrations 
in yeast89. High iron concentrations increased sphingolipid levels which activate the 
Pkh/Ypk cascade leading to phosphorylation and inactivation of the Orm proteins. 
Over-expression of Orm2 is inhibiting this response and reduces Ypk phosphorylation 
thereby maintaining balanced sphingolipid levels89. 
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In mammalians three ubiquitously expressed ORMDL isoforms are known: ORMDL1 
(Swiss-prot: Q9P0S3), ORMDL2 (Swiss-prot: Q53FV1) and two variants of 
ORMDL390 (Swiss-prot: Q9P0S3-1 and -4). The three isoforms are highly identical in 
their protein sequences (81-84%) and were found to be extremely conserved between 
vertebrate species. All ORMDL isoforms co-localized with ER markers82 and 
ORMDL3 was found to physically interact with the SPTLC1 subunit84. The silencing 
of all three ORMDL isoforms resulted in increased de novo formation of ceramides84, 
91 indicating that ORMDL proteins are also negative regulators of the mammalian 
SPT. Moreover, it was shown that ORMDL proteins suppress SPT activity under 
normal growth conditions and that the presence of serum in the growth media has an 
additional non-ORMDL mediated inhibitory effect on ceramide synthesis91. The 
authors showed that ORMDL proteins affect solely SPT activity and had no effect on 
ceramide synthases91.  
In contrast to yeast it is not known how the ORMDL proteins inhibit SPT, since the 
mammalian ORMDL proteins are N-terminally truncated in comparison to their yeast 
homologs and lack the serine residues that are phosphorylated by Ypk1 in yeast82, 84. 
The mammalian ORMDL proteins also lack the canonical phosphorylation motif for 
the mammalian Ypk-homolog - the serum and glucocorticoid-induced kinase (SGK). 
This leaves the question open whether ORMDL proteins in the mammalian system act 
in the same way as it is described in yeast.  
Furthermore, the mechanism how the cell senses the ceramide status is not 
understood. It has been suggested that a downstream metabolite of the synthesis 
pathway like ceramide or even higher complexity substitute (e.g. sphingomyelin or 
glycosphingolipids) could drive this mechanism, since the sphingosine induced 
inhibition of SPT was lost when cells were co-stimulated with FB1 which prevents 
the conversion of the added sphingosine to complex sphingolipid-species91.  
ORMDL3 has been identified as a significant risk factor for early childhood asthma in 
several genome-wide association studies92-95. This can be linked to the recent finding 
that ORMDL3 expression is induced in the lung epithelium by allergens and 
cytokines (IL-4 or IL-13)96. ORMDL3 mRNA expression is strongly dependent on 
STAT-6 and the expression of ORMDL3 in lung epithelium cells induced 
metalloproteases, chemokines as well as oligo-adenylate synthetases genes and 
triggered the unfolded protein response (UPR) via activation of ATF6. Jin and 
colleagues found higher ORMDL3 mRNA expression in the peripheral blood of 
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patients experiencing wheezing compared to healthy controls. A specific analysis of 
the ORMDL3 promoter indicated the involvement of the transcription factors Ets-1, 
p300 and CREB to control ORMDL3 expression97. All three transcription factors are 
involved in regulating inflammatory processes underlying the association of elevated 
ORMDL3 levels with asthma or inflammatory diseases.  
ORMDL3 was also found to bind to the sarco-endoplasmatic reticulum calcium pump 
(SERCA) thereby inhibiting the transport of calcium from the cytosol to the ER which 
leads to a reduced ER calcium content. This results in a UPR response which 
mediates NFκB- and JNK-activation and leads to a pro inflammatory response98, 99. 
Furthermore, an increased ORMDL3 mRNA expression was associated with  
decreased T-lymphocyte activation which provides a further functional link between 
the genetic association of ORMDL3 and inflammatory diseases100. Last but not least a 
reduced expression of ORMDL1 (also called Adoplin-1) was found to be associated 
with mutations in presenilin which is part of the γ-secretase complex that mediates the 
cleavage of amyloid precursor protein (APP)101. A knock-down of ORMDL1 led to a 
reduced γ-secretase activity indicating that ORMDL1 could also be a therapeutic 
target for treating Alzheimer’s disease101. 
 
Small SPT subunits activate SPT activity and affect acyl-CoA specificity 
A group of small proteins, designated as “small subunits SPT a and b”(ssSPTa/b) 
were shown to interact with SPTLC1/ SPTLC2 and SPTLC1/SPTLC3 heterodimers 
thereby generally increasing SPT activity and influencing acyl-CoA specificity102. A 
homologous protein (Tsc3) was found earlier in yeast103.  In detail, co-expression of 
mammalian ssSPTa and ssSPTb in combination with either SPTLC1+SPTLC2 or 
SPTLC1+SPTLC3 in a yeast strain which lacks the endogenous SPT expression 
resulted in a significant increase of overall SPT activity. The activity increase was 
more pronounced upon co-expression of ssSPTa than of ssSPTb. It was shown that 
both small subunits interact directly with the SPTLC1 subunit. Moreover, it was 
demonstrated that co-expression of ssSPTa and b with the individual SPTLC subunits 
alter the preference of the enzyme for acyl-CoAs with different carbon chain lengths. 
A complex consisting of SPTLC1/SPTLC2/ssSPTa showed a higher preference for 
C16-CoA resulting in C18-derived sphingoid bases whereas a complex of 
SPTLC1/SPTLC3/ssSPTa preferentially used C14-CoAs forming C16-based 
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sphingoid bases. This is in line with previous findings that the SPTLC3 subunit has a 
higher specificity towards shorter acyl-CoAs like myristoyl- and lauryl-CoA whereas 
the SPTLC2 subunit preferentially uses palmitoyl C16-CoA76. The ssSPTb subunit 
modulates the preference of SPT for longer acyl-CoAs like stearyl C18-CoA which 
results in the generation of C20-derived sphingoid bases. Long chain acyl-CoAs were 
mostly generated by the combination SPTLC1/SPTLC2/ssSPTb whereas a 
SPTLC1/SPTLC3/ssSPTb constellation metabolized a broad range of acyl-CoAs 
without any apparent preference102. Based on this report small SPT subunits modulate 
overall SPT activity but also the generation of specific sphingolipid-species. 
 
Other known and proposed binding partners of SPT 
In addition to the ORMDL and ssSPTa/b regulators other proteins have been 
described to be associated with the SPT subunits. Inuzuka et al. described a novel 
class of endoplasmatic proteins, named Serine Incorporator (Serinc1-5) in yeast and 
mammalian cells that can increase the synthesis of phosphatidylserine and 
sphingolipids104. Yeast-two hybrid experiments revealed a potential binding of 
Serinc1 to SPTLC1 (LCB1) as well as to PGDH (yeast: SER3), an enzyme that 
catalyzes the first and rate-limiting step in serine synthesis. Overexpression of Serinc1 
doubled SPT activity in COS cells. The authors speculate that Serinc could act as a 
platform to facilitate the interaction of the soluble L-serine with the membrane bound 
SPT 104. Several regulatory sites have been identified in Serinc1 including- 
phosphorylation39, 50, myristoylation105 and glycosylation53 sites, but no functions 
were connected to them yet.  
Large-scale proteomic screens aiming to identify protein-protein interactions revealed 
several further potential binding partners for SPTLC2 in S. cerevisiae (LCB2)106. The 
identified proteins (Bmh1,2; Crm1; Ecm29; Fks1; Gea2; Gfa1; Kap104; Kap123; 
Lcb1; Lcb2; Lys12; Mir1; Sam1,2; YHR020W) are involved in growth regulation, 
protein transport and nuclear import and export, amongst others. Moreover, a 
genome-wide yeast two hybrid analysis suggested 13 potential binding partners for 
SPTLC2 in drosophila (lace2)107. Among these potential binding partners for lace2 
(Hsc70-4; CG4287; RpS27A; CG5802; CG6126; Vha13; CG6453; CG9986; 
CG4162; RPL31; CG32758; CG4046; CG4193) are ribosomal proteins, heat shock 
proteins, thioredoxin and transmembrane transporters.  
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SPTLC1 has also been proposed to act via its PDZ binding motif with several other 
proteins including Par3, ABCA1, FRMPD4 and PTPN13108, 109. SPTLC1 was shown 
to interact with ABCA1 in THP1 monocyte-derived macrophages and in mouse liver. 
It has been proposed that the binding of ABCA1 to SPTLC1 inhibits the cholesterol 
efflux activity thereby maximizing the cellular cholesterol in cells with a high demand 
for membrane synthesis109. Moreover Par3, a scaffolding factor that recruits signaling 
molecules into multiprotein complexes, was identified to bind SPTLC1 in THP1-
derived macrophages and in mouse liver. Knocking-down Par3 or SPTLC1 decreased 
both, SPT activity and chemotaxis induced migration of THP1 monocytes108. This 
suggests that the migration in monocytes involves sphingolipids and depends on the 
recruitment of SPTLC1 by the scaffolding factor Par3. 
 
Serine palmitoyltransferase and hereditary sensory neuropathy type I 
Several missense mutations in the SPTLC1 and SPTLC2 gene were associated with 
hereditary sensory and autonomous neuropathy type I (HSAN I)110-117. HSAN I is an 
autosomal dominantly inherited peripheral neuropathy with a primarily sensory (heat, 
pain, vibration) and a variable motor component. The disease is characterized by a 
length dependent axonal loss with a typically late onset in the second or third decade 
of life114. Due to the sensory loss, patients suffer from painless injuries, chronic skin 
ulcers and Charcot joints frequently requiring amputations. The variable motor 
component is characterized by variable muscle wasting primarily in the extremities 
and the need for orthopedic aids at later stages.  
An increasing number of point mutations in the SPTLC1 and SPTLC2 genes were 
associated with HSAN I. They include mutations in SPTLC1 (C133W110-112, 
C133Y112, V144D112 , G387A118, S331F and A352V119, C133R - personal 
communication) and in the SPTLC2 subunit (V359M, G382V, I504F116 and T409M-
unpublished). No HSAN I causing mutation was found in the SPTLC3 yet. All 
confirmed HSAN I mutations  resulted in decreased activity with L-serine in isolated 
proteins although this reduced activity does not transform into reduced total 
sphingolipid levels in mutant expressing cells or plasma of HSAN I patients 116, 120.   
Interestingly, besides the reduction of canonical activity, the HSAN I mutations 
induce a shift in the amino acid substrate, leading to the metabolism of L-alanine and 
to a certain extent L-glycine as alternative substrates. This results in the formation of 
atypical 1-deoxy-sphingolipids (dSLs) which lack the C1-hydroxyl-group of normal 
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ceramides114, 118, 119. The dSLs are therefore not converted to complex sphingolipids. 
Also degradation by the canonical pathway is hampered, since the formation of 
sphingosine-1-phosphate as a catabolic intermediate is not possible. Elevated dSL 
levels were found in plasma and peripheral nerve tissue (PNS) of transgenic HSAN I 
mice121 and in the plasma of HSAN I-patients116, 120. Deoxy-sphingolipids were shown 
to be neurotoxic in cultured DRG neurons by affecting number and length of neurite 
outgrowth120. The dSL formation could be suppressed in HSAN I mutant cells and 
transgenic HSAN I-mice121 by supplementation with L-serine. Upon L-serine 
supplementation, plasma dSL levels normalized and the HSAN I transgenic mice did 
not develop any neurological defects up to an age of 20 month. The dSL-lowering 
effect in plasma due to oral L-serine supplementation was confirmed in a 10 week 
pilot study with 20 HSAN I patients. Improvements in the neuropathy were not 
addressed in that study. A comprehensive clinical trial over a period of 24 months is 
currently planned and will start in late spring 2013.  
 
Other factors that contribute to deoxy-sphingolipid generation 
Deoxy-sphingolipids can also be formed in the absence of mutations in SPT. Low but 
detectable dSL levels are generally found in plasma - also of healthy individuals. 
However, patients with metabolic syndrome or diabetes type 2 have significantly 
elevated plasma dSL levels122, 123. This shows that not only the mutant but also the 
wildtype SPT is capable of producing dSLs under certain conditions. The addition of 
Fumonisin B1 (FB1) - an inhibitor of Ceramide Synthase (CerS) – was shown to 
significantly stimulate dSL formation in cultured cells124. Also culturing cells at a 
high density for a prolonged time increases dSL formation124. Whether dSLs have a 
physiological role in lipid metabolism is not clear yet. Recently, deoxy-ceramides 
were identified as scaffold lipids facilitating lipid antigen presentation and suggesting 
a role in the innate immunity125. Another report showed that dSLs accumulate 
together with ceramides upon TNFa stimulation126. However, the observation that wt 
SPT forms dSL only under certain, not yet well defined conditions, argues for a 
regulatory mechanism allowing SPT to shift between L-serine and L-alanine as 
substrates.  
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Aim of the thesis 
The aim of this thesis was to identify and characterize regulatory mechanisms that 
underlie the change in amino acid substrate specificity and dSL formation of wild 
type and mutated SPT. 
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Abstract 
 
Objective:  
To describe the clinical and neurophysiological phenotype of a family with hereditary 
sensory and autonomic neuropathy type I (HSAN I) due to a novel mutation in 
SPTLC2 and to characterize the biochemical properties of this mutation. 
 
Methods: 
We screened 107 patients with HSAN who were negative for other genetic causes for 
mutations in SPTLC2. The biochemical properties of a new mutation were 
characterized in cell-free and cell based activity assays.  
 
Results: 
A novel mutation (A182P) was found in two subjects of a single family. The 
phenotype of the two subjects was an ulceromutilating sensory-predominant 
neuropathy as described previously for patients with HSAN I, but with prominent 
motor involvement and earlier disease-onset in the first decade of life. Affected 
patients had elevated levels of plasma dSLs. Biochemically the A182P mutation was 
associated with a reduced canonical activity but an increased alternative activity with 
alanine, which results in largely increased dSL levels, supporting their pathogenicity. 
 
Conclusion:  
This study confirms that mutations in SPTLC2 are causing HSAN I and are associated 
with increased dSL formation. 
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Introduction 
 
Hereditary sensory and autonomic neuropathy type 1 (HSAN I) is an autosomal 
dominant (AD) sensory neuropathy complicated by ulcerations and amputations, with 
variable autonomic and motor involvement1. To date, mutations in five genes have 
been reported to cause AD HSAN I2-7.  
Mutations in the enzyme serine palmitoyltransferase (SPT) cause HSAN I8, 9. SPT is a 
heteromeric enzyme composed of three subunits (SPTLC1-3) located at the outer 
membrane of the endoplasmic reticulum 10, 11. It catalyzes the first and rate-limiting 
step in de novo sphingolipid synthesis: the condensation of L-serine and palmitoyl-
CoA. Mutations in SPTLC1 account for 12% of patients with HSAN12. More recently, 
mutations in SPTLC2 were found to cause HSAN I with a similar phenotype13. HSAN 
I mutations cause a shift in the substrate specificity of SPT leading to the alternative 
use of L-alanine and L-glycine over its canonical substrate L-serine 14,15. This forms 
an atypical category of 1-deoxy-sphingolipids (dSLs) lacking the C1 hydroxyl group 
which impedes their conversion into complex sphingolipids but also their canonical 
degradation. Elevated dSLs were found in the plasma and lymphoblasts of HSAN I 
patients14 as well as in plasma and tissues of transgenic HSAN I mice16. DSLs were 
shown to be neurotoxic blocking neurite formation in cultured neurons14.  
Here we report a novel HSAN I mutation in SPTLC2 that is associated with elevated 
plasma dSLs. Analysing SPT activity in isolated proteins as well as in living cells 
show that this mutant has reduced canonical activity but forms high levels of dSLs.  
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Methods 
 
Standard Protocol Approvals, Registrations, and Patient Consents 
Ethical approval for this study was obtained from the Joint Medical and Ethics 
Committee at the National Hospital for Neurology and Neurosurgery (NHNN). 
Written informed consent was obtained from all patients.  
Patients 
107 patients with HSAN were selected from our inherited neuropathy database 
including patients seen in the NHNN peripheral neuropathy clinics as well as patients 
whose DNA were referred from other hospitals for diagnostic and research testing.  
Most patients presented with distal progressive sensory loss, with or without 
ulceromutilating complications or autonomic dysfunction. Because of the overlap 
between Charcot-Marie-Tooth Type 2B (CMT2B) and HSAN I, we included patients 
with motor involvement; however, sensory features were predominant. Diagnosis was 
based on clinical phenotype in addition to neurophysiology. All patients were 
negative for mutations in SPTLC1 and most were also negative for mutations in 
RAB7, NGFB, FAM134B and NTRK1. Three hundred and fifty-eight British control 
chromosomes were screened for control. 
 
Patient assessment 
Patients found to have mutations underwent detailed clinical and neurophysiological 
assessments including the Charcot-Marie-Tooth Neuropathy Score 2 (CMTNS2)17. 
Nerve conduction studies were performed using standard technique. 
 
Genetic sequencing 
All 12 exons and flanking introns of SPTLC2 were amplified using Roche polymerase 
chain reaction (PCR) reagents. Sequence reactions were performed using Big Dye 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and resolved on an ABI 
3730xl Sequencer. See Supplemental Figure 1 for primers and primer conditions. 
Sequence variants were confirmed by repeat sequencing. PolyPhen2 
(http://genetics.bwh.harvard.edu/pph/), SIFT (http://blocks.fhcrc.org/sift/SIFT.html) 
and aGVGD (http://agvgd.iarc.fr/), were used to predict the effect of the mutation on 
protein function. 
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Cloning 
The A182P was introduced into the SPTLC2 cDNA by site-directed mutagenesis as 
described earlier18 using the following primers: SPTLC2_A182P_fw: CAA CTA TCT 
TGG ATT TCC CCG GAA TAC TGG ATC ATG and SPTLC2_A182P_rv: CAT 
GAT CCA GTA TTC CGG GGA AAT CCA AGA TAG TTG. All constructs were 
verified by sequencing. 
 
Stable expression of SPTLC2wt and the A182P mutation in HEK293 cells 
HEK293 (ATCC) were stably transfected with the empty vector (control), SPTLC2wt 
or the A182P mutant as described previously18. Expression of the constructs was 
confirmed by RT-PCR and immune blotting (Supplemental Figure 2). 
 
Immunostaining of stable expressed SPTLC2 variants in HEK293 cells   
HEK293 cells transfected with wtSPTLC2 and SPTLC2-A182P were cultured in 
chamber culture slides (BD Falcon) to 50% confluence and fixed in 4% 
paraformaldehyde for 15 min at 37°C. Permeabilization was performed for 5min 
using ice-cold acetone.  Cells were washed in double-distilled water and dried for 
some seconds. Unspecific binding sites were blocked with 1% horse serum in PBS for 
30min. After washing in PBS, mouse anti-V5-tag antibody diluted 1:2000 (Serotec) in 
blocking solution together with rabbit anti-calnexin antibody 1:4000 (Sigma) were 
incubated for 2 hours. After 2 times washing in PBS, Alexa Fluor 594 conjugated 
secondary goat anti-mouse antibody (Invitrogen) diluted 1:1000 in blocking solution 
was incubated together with 30nM DAPI for 1 hour in the dark. Immunofluorescence 
of the V5 tagged SPTLC2 mutant and wildtype protein, calnexin and nucleinacid 
were detected with Zeiss Axiovert 200M using AxioVision 4 software. 
 
Metabolic labeling assay 
Transfected HEK293 cells were cultured in DMEM for three days before medium was 
changed to DMEM without L-serine (Genaxxon BioScience). After two hours pre-
incubation, isotope labeled (2,3,3-d3, 15N) L-serine (1mM) and (2,3,3,3)-d4 labeled 
L-alanine (5mM, Cambridge Isotope Laboratories, Inc.) was added to the cells. In 
some cases, cells were treated with Fumonisin B1 (35uM) as described. Cells were 
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harvested after 24h, counted (Z2 Coulter Counter, Beckman Coulter) and pelleted 
(800xg, 5min at 4°C). Pellets were stored at -20°C.  
 
SPT activity assay in isolated proteins and lipid base extraction 
Total protein was extracted from frozen HEK293 cell pellets using SPT assay buffer 
(50mM HEPES pH8, 1mM EDTA, 0.2% Triton-X). 500ug total protein was added to 
a mix of 160uM palmitoyl-CoA (Sigma), 30uM pyridoxal-5'-phosphate (Sigma) and 
either 64mM L-serine or 320mM L-alanine (Sigma). The mix was incubated for 
45min at 37°C under constant shaking at 800 rpm (Thermomixer comfort, 
Eppendorf). The in vitro SPT reaction was stopped by adding 500ul lipid extraction 
buffer containing 4 vol MetOH-KOH and 1 vol CHCl3 spiked with 200 pmol isotopic 
labeled d7-sphinganine and d7-sphingosine (Avanti Polar Lipids) as internal 
extraction standards. Lipids were base-extracted and analysed as described18. 
 
Acid-base extraction and analysis of sphingoid bases 
500ul MetOH including 200pmol internal standard (d7-sphinganine and d7-
sphingosine, Avanti Polar Lipids) were added to 100ul of plasma or frozen cell pellets 
re-suspended in 100ul PBS. Lipid extraction was performed for 1hour at 37°C with 
constant agitation at 1000 rpm (Thermomixer comfort, Eppendorf). Precipitated 
protein was removed by centrifugation (5min at 16000xg). After transferring  the 
supernatant into a new tube, lipids were extracted, acid-base hydrolysed and analyzed 
by LC-MS as described earlier14.  
 
Statistics 
One-way ANOVA was used for statistical analysis. Significance was verified by 
Bonferroni multiple-correction.  P-values less than 0.001 were considered significant 
unless otherwise stated (****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). 
Statistical analysis was performed using GraphPad Prism5. 
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Results 
 
Genetics 
Sequencing of SPTLC2 in 107 index patients with HSAN I revealed a novel mutation 
in one family. c.544G>C, A182P, was found in the index case (Figure 1A; III-2); this 
mutation was not present in 358 control chromosomes. One other affected member of 
this family who was tested carried the mutation (Figure 1A; IV-2). 
 
FIGURE 1A: Pedigree of HSAN I family with A182P-SPTLC2 mutation  
Square = male; circle = female; diagonal line = deceased; filled symbol = affected;  
m / + = heterozygous for mutation; arrow = proband; electropherogram of affected 
patient and control 
 
The A182P mutation affects a highly evolutionary conserved amino acid (Figure 1B); 
PolyPhen2 and SIFT both predict that this change would be damaging, while aGVGD 
classes the variant as class C25 where C65 is most likely to interfere with function 
and C0 less likely to interfere with function. 
 
FIGURE 1B: Conservation of A182P in different species 
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Clinical details 
The family had autosomal dominant (AD) inheritance (Figure 1A). Clinical features 
are documented in Table 1. Both patients had onset in the first decade, presenting with 
reduced sensation in the feet, with later development of motor weakness. Sensory loss 
occurred in a glove and stocking distribution; pinprick perception was affected to a 
greater extent than vibration perception, similar to patients with SPTLC1 mutations19. 
III-2 had painful tingling in the hands while IV-2 had no history of pain. Sensory 
complications including ulcers and accidental burns occurred in both patients. In both 
patients severe wasting and weakness was present (Figure 1C). There were no 
symptoms of hearing loss or autonomic dysfunction. 
 
 
FIGURE 1C: SPTLC2 A182P patients 
Photograph of IV-2 (A, B) and III-2 (C, D) demonstrating marked wasting and weakness in 
upper and lower limbs  
 
Neurophysiology 
Table 2 describes the neurophysiology of the HSAN I patients. Although this was 
predominantly an axonal neuropathy, motor conduction velocities in the upper limbs 
were slow (<38 m/s) even in the patient III-2 who had reasonable upper limb motor 
amplitudes, a finding which we have previously documented in our HSAN I families 
with SPTLC1 mutations19. 
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Table 1: Clinical details 
 
Patient Age 
last 
exam
Sex AAO Symptoms at 
onset 
Positive 
sensory 
symptoms
Motor 
UL / LL 
Sensory Ulcers Amputations Reflexes CMTNS2  
III-2 63 F 10 Numb feet Painful 
tingling in 
hands 
Severe 
distal UL 
and LL 
Vib to knees, 
pin above 
wrists and 
above knees
Burns No Brisk UL, 
absent at 
ankles 
25/36 
IV-2 29 F 5 Numb feet No Mild 
proximal 
and 
severe 
distal UL / 
severe 
distal LL
Vib to ankle, 
pin above 
elbow and 
above knee 
Burns No Brisk UL, 
reduced at 
ankle 
27/36 
Table 1: Clinical details  
AAO = age at onset; UL = upper limbs; LL = lower limbs; CMTNS2 = Charcot-Marie-Tooth Neuropathy Score version 2 17 F = female; Vib = vibration;  
 
Table 2: Nerve conduction studies  
 
 
 
 
 
 
Table 2: Nerve conduction studies  
DML = distal motor latency; CV = conduction velocity; CMAP = compound motor action potential; SAP = sensory action potential; ms = milliseconds; m/s = 
metres per second; mV = millivolts; uV = microvolts 
Patient Median Ulnar Radial Common peroneal Sural
 DML 
ms 
CV 
m/s
CMAP 
mV 
SAP 
uV 
DML 
ms
CV 
m/s
CMAP 
mV
SAP 
uV
SAP 
uV
DML 
ms 
CV 
m/s
CMAP 
mV
SAP uV
 III-2 3.5 32 4.5 NR 3.9 33 3.1 NR NR NR  NR NR
 IV-2 4.1 25 0.2 NR 4.1 29 0.3 NR NR 5.4 30 0.2  
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Plasma sphingoid- and deoxy-sphingoid base levels  
Total sphinganine (SA) or sphingosine (SO) base levels showed no difference 
between SPTLC2-A182P patients and healthy controls, whereas dSL levels were 
elevated in plasma of the two A182P carriers. Higher dSL plasma levels were found 
in the more severely affected patient, IV-2 (Figure 3). 
 
A:          B:      
      
FIGURE 3: Sphingoid base and deoxy-sphingoid base levels 
Total sphingoid base (A) and deoxy-sphingoid base (B) levels in plasma of patients and 
healthy controls. There are significant differences only for deoxy-sphingoid base levels in 
patients carrying the SPTLC2 A182P mutation (p < 0.001 for III-2 and p < 0.0001 for IV-2). 
Data are shown as mean, with error bars representing standard deviations. Error bars and 
standard deviation were calculated using 1-way ANOVA with Bonferroni's Multiple 
Comparison Test. SA, sphinganine; SO, sphingosine; 1-deoxySA, 1-deoxy-sphinganine; 1-
deoxySO, 1-deoxysphingosine  
 
Effect of the SPTLC2-A182P mutation on SPT activity  
Most of the HSAN I mutations in SPTLC1 and SPTLC2 are associated with reduced 
canonical activity in a cell-free environment and increased dSL formation in living 
cells8, 9, 13, 20. The A182P mutant showed a 65% reduced activity with L-serine and a 
3.5-fold increased activity with L-alanine when analysed in isolated proteins (Figure 
4A-B). These results were confirmed by a metabolic labeling assay in living cells 
using isotope labeled (d3, N15) L-serine (1mM) and (d4) L-alanine (5mM) which 
leads to the formation of isotope labeled (M+3)SA and (M+3)deoxySA since one 
deuterium is lost during the reaction the condensation reaction21. This assay was 
performed in the presence or absence of Fumonisin B1 (FB1), an inhibitor of 
ceramide synthase (CerS). The inhibition of CerS leads to a significant accumulation 
of SA over time which is a measure for cellular SPT activity. Upon FB1 treatment, 
SPTLC2wt cells showed a 2-3 fold higher accumulation of (M+3) SA and (M+3) 
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deoxySA compared to controls (Figure 4C-D). The formation of (M+3) SA was 
decreased by 50% in the A182P mutant cells (Figure 4C). Compared to SPTLC2wt 
cells, (M+3) deoxySA formation was 15-fold higher in A182P cells (Figure 4D). In 
the absence of FB1 sphingoid bases are mostly metabolized into ceramides and 
complex sphingolipids which results in a predominant release of (M+3)SO after acid 
hydrolysis (Figure 4C). In contrast, deoxySLs were predominantly present as (M+3) 
deoxySA (Figure 4D). In SPTLC2wt cells the total sum of isotope labeled sphingoid 
bases was 50% higher in FB1 treated than in non-treated cells. In the absence of FB1 
the canonical activity was the same in A182P and SPTLC2wt cells (Figure 4C). In the 
absence of FB1 no isotope labeled dSLs were found in SPTLC2wt cells. In contrast, 
labeled dSLs were detected in A182P cells although the total levels were about 8-fold 
lower than under FB1 treatment (Figure 4D). Since FB1 had no effect on SPT activity 
in isolated proteins (data not shown) we assume that the stimulatory effect of FB1 on 
SPT activity is indirect and probably associated with a recently described metabolic 
feedback regulation22-24. 
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A:      B: 
 
 
C:      D: 
 
FIGURE 4: SPT activity in cell-free conditions (A, B) and in intact HEK293 cells 
(C, D) 
SPT activity in isolated proteins with L-serine (A) and L-alanine (B) measured in 1mg total 
protein lysate extracted from HEK293 cells expressing wt or mutant SPTLC2 
(A) The A182P mutation leads to a significant decrease (p < 0.001) in keto-SA compared to 
the SPTLC2 wt expressing control.  
(B) The A182P mutation leads to a significant increase (p < 0.0001) in keto-deoxySA 
compared to the SPTLC2 wt expressing control. 
(C) Canonical SPT activity measured in HEK293 cells  
SPT activity in the SPTLC2 wildtype is increased in the presence of FB1 (p < 0.0001), while 
this FB1-dependant increase is lost in the mutant A182P. Without the usage of FB1, SPT 
activity is not different in the mutant compared to the wt SPTLC2. 
(D) Generation of dSLs in HEK293 cells  
The A182P mutation leads to a significant increase (p < 0.0001) in dSL species in the 
presence and absence of FB1compared to the SPTLC2 control. FB1 per se leads to generation 
of dSLs in SPTLC2 wt (p < 0.001) and to a large increase in dSLs in the mutant SPTLC2 (p < 
0.0001). 
Data are shown as mean, with error bars representing standard deviations. Error bars and 
standard deviation were calculated using 1-way ANOVA with Bonferroni's Multiple 
Comparison Test. Wt wildtype, SA sphinganine, SO sphingosine, deoxy-SA deoxy-
sphinganine, deoxy-SO deoxy-sphingosine, dSLs deoxy-sphingolipids, FB1 Fumonisin B1,  
mg milligram 
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No differences in the spatial distribution were seen between STPLC2wt and the 
A182P mutant. Immune-histochemistry showed in both cases a co-localisation with 
the ER marker calnexin (Figure 5). 
 
SPTLC2 wt: 
Calnexin            V5-antibody   Overlay 
   
Calnexin            V5-antibody    DAPI 
    
 
SPTLC2_A182P: 
Calnexin             V5-antibody   Overlay 
   
Calnexin             V5-antibody   DAPI 
      
FIGURE 5: Co-localization of HEK293-SPTLC2 wt and -A182P with ER marker 
Calnexin 
Localization of transfected wt (SPTLC2) and mutant-SPTLC2 (A182P) in HEK293 cells 
revealed co-localization of both variants with the ER marker calnexin (blue DAPI; green 
calnexin; red SPTLC2 variants.  
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Discussion 
 
Mutations in SPTLC1 are a well-established cause of HSAN I8, 9, 19. An initial study of 
12 families with HSAN I did not find any patients with mutations in SPTLC225. 
However, because of the known association of SPT with HSAN I, SPTLC2 remained 
a functional candidate and a later study established that mutations in SPTLC2 were 
also associated with HSAN I13. Our study provides genetic and functional data 
demonstrating that a novel A182P mutation found in one family is pathogenic, and 
gives detailed clinical and neurophysiological descriptions of the phenotype. The age 
of onset in this family was in the first decade, younger than is typically seen in HSAN 
I patients. To date, three HSAN I mutations in SPTLC2 have been described (V359M, 
G382V and I504F). Of these, one was associated with early onset in the first decade 
and other atypical features like motor conduction velocities in the demyelinating 
range, suggesting a wide phenotypic spectrum of HSAN I. Elevated blood dSL levels 
were confirmed in both A182P carriers with higher levels being found in the more 
severely affected daughter than the mother. The A182P mutant showed a significantly 
reduced activity with L-serine and increased activity with L-alanine when analysed in 
isolated proteins. This was confirmed by two metabolic labelling assays in living 
cells. The combined genetic, clinical and functional data confirm the association of 
this novel SPTLC2 mutation with HSAN I. It further supports the concept that a 
pathological dSL formation underlies the pathogenesis of HSAN I indicating that 
HSAN I, in contrast to most other inherited neuropathies, is a metabolic disorder. The 
dSLs are therefore relevant HSAN I biomarkers to validate the functional 
consequences of genetic SPTLC1 and SPTLC2 variants.  
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Footnotes 
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Supplemental information 
 
 
SUPPLEMENTAL FIGURE 1: Primer for sequencing 
PCR comprised the following steps for all exons except exons 1 and 5: 1) 95°C for 15 
minutes, 2) 25 cycles of 95°C for 30 seconds, 60°C (reduced by 0.4°C per cycle) for 30 
seconds, and 72°C for 45 seconds, 3) 13 cycles of 95°C for 30 seconds, 50°C for 30 seconds, 
and 72°C for 45 seconds, 4) 72°C for 10 minutes. 
For exon 1: 1) 95°C for 15 minutes, 2) 38 cycles of 95°C for 30 seconds, 58°C (reduced by 
0.4°C per cycle) for 30 seconds, and 72°C for 45 seconds, 3) 72°C for 10 minutes. 10% 
DMSO 
For exon 5: 1) 95°C for 15 minutes, 2) 37 cycles of 95°C for 30 seconds, 51.3°C (reduced by 
0.4°C per cycle) for 30 seconds, and 72°C for 45 seconds, 3) 72°C for 10 minutes. 
 
 
A:         B: 
              
SUPPLEMENTAL FIGURE 2: mRNA and protein expression in wt and mutant 
SPTLC2 transfected HEK293 cells 
mRNA (A) and protein (B) expression levels are not different in the expressed SPTLC2 
wildtype and mutant in HEK293 cells 
SPTLC2 protein 62.9kDa, and beta-actin 41.7kDa (loading control) detected with V5/His-
antibody 1:200
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SPTLC2 exon Forward primer Reverse primer Primer conditions 
1 CCTACAGAGCCTGCCTTG CGGTGTGGACTGGCGGAG 58 touchdown 
2 GGTATAATTCAGCAAATCTC TTTAACTGCATCTGGAATAG 60-50 touchdown 
3 TAATGAAATTGCCCTTATAC AATCATATTGTATCCTCAGC 60-50 touchdown 
4 ATAGACTTTGTTCTCTCTGC CTAAATGACATGACAAAGTG 60-50 touchdown 
5 TCTGAAAAGGACACAACAC TTTAGCTCACTCTGACTGC 51.3 
6 AGCTATTAGTGTTTGTGGC TCATTTATACTTTCAAGTGC 60-50 touchdown 
7 TATCTGAGGCATGGTTTC TAGACTAATGTTCCCTTCAG 65-55 touchdown 
8 ATAATAATGAAGTGCCAAAC GTATTATGAGCCTAAACCAG 60-50 touchdown 
9 TCTAGAACTTAGAAGGAAAGG TGCCTATTAGTAAACCTGAC 60-50 touchdown 
10 GATAGAATGGAGATAGAGGAG TAAGGACAAGACCATTTTC 60-50 touchdown 
11 TTGAAATCTTTGAGGACAG GCTCACAAGAACATCAAG 60-50 touchdown 
12 GCACTAGACATAAGTCCTGC ACAGAAGTGTGGTTCCTG 60-50 touchdown 
vector SPTLC2 SPTLC2_ 
A182P 
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Capsule  
Background: The inherited neuropathy HSAN I is associated with increased formation of 1-
deoxy-sphingolipids. No mechanistic details are known that lead to their generation. 
Results: We report a novel HSAN I-causing mutation (SPTLC2-S384F) at the same position 
as a putative phosphorylation site. 
Conclusion: S384 is a regulatory site in SPTLC2 that influences amino acid substrate-
specificity of SPT 
Significance: The regulation of 1-deoxy-sphingolipid formation is essential for understanding 
their physiological meaning. 
 
Summary  
1-Deoxy-sphingolipids (dSLs) are atypical sphingolipids which are formed by the enzyme 
serine palmitoyltransferase (SPT) due to a promiscuous use of L-alanine over its canonical 
substrate L-serine. Several missense mutations in SPT cause the rare, inherited sensory 
neuropathy HSAN I and are associated with pathologically increased dSL levels. Metabolic 
diseases like the metabolic syndrome and diabetes are also associated with an increased 1-dSL 
formation. The mechanism underlying the switch in substrate specificity for the wt SPT is not 
understood. In a comprehensive screen for new HSAN I mutations we identified a novel 
SPTLC2-S384F variant in two unrelated HSAN I families. Plasma samples from the index 
patients showed increased dSL levels and ectopic expression of the S384F mutant in HEK293 
cells resulted in increased dSL generation. Two phosphorylation sites in the SPTLC2 subunit 
(S384 and Y387) were reported previously from an unbiased phospho-proteome screen. Both 
sites are located in close vicinity to the active site of the enzyme and might thereby be 
involved in regulating SPT activity and substrate specificity. A phosphorylation of SPTLC2 
was confirmed by isoelectric focusing. We therefore tested the role of these two sites by 
creating a set of mutants which mimicked either a constitutively phosphorylated (S384D, 
S384E) or unphosphorylated (S384A, Y387F, Y387F+S384A) SPTLC2 subunit. Only the 
S384D but not the homologue S384E nor the negative mutants were associated with increased 
dSL formation. Our data suggest that phosphorylation at S384 could act as a molecular switch 
shifting SPT activity from metabolizing L-serine to L-alanine. 
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Introduction  
Serine palmitoyltransferase (SPT) catalyzes the condensation of L-serine and palmitoyl-CoA 
which is the first and rate limiting step of ceramide de novo synthesis 1, 2. Under certain 
conditions the enzyme shows a switch in substrate specificity and uses also L-alanine as an 
alternative substrate. This reaction leads to the formation of an atypical class of 1-deoxy-
sphingolipids (dSLs) which lack the C1 hydroxyl group of regular sphingoid bases3, 4. These 
atypical 1-deoxy-sphingoid bases are metabolized to 1-deoxy-(dihydro)-ceramides4  but 
cannot be converted to higher substituted sphingolipids due to the missing hydroxyl group. 
Accordingly, they are not degraded by the canonical sphingolipid catabolism which involves 
the phosphorylation at C1 to form sphingosine-1-phosphate as a catabolic intermediate 
(Supplemental Figure 1). 
Several point mutations in SPTLC1 and SPTLC2 cause the rare inherited sensory neuropathy 
HSAN I (Hereditary Sensory and Autonomic Neuropathy type I)5-12. All confirmed HSAN I 
mutations in SPT revealed a reduced canonical activity with L-serine in isolated proteins and 
a significantly increased activity with L-alanine in intact cells3, 12. Elevated dSL levels are 
found in plasma and peripheral nerve tissue (PNS) from transgenic HSAN I mice13 and in the 
plasma of patients3, 12 and are therefore considered to be a biochemical hallmark for HSAN I. 
Moreover, patients with a deregulated carbohydrate metabolism like the metabolic syndrome 
and diabetes14-16 exhibit elevated dSL plasma levels, even though there are no underlying 
mutations in SPT. This shows that not only the mutant, but also the wildtype SPT is capable 
to form dSL under certain conditions. Moreover, the presence of Fumonisin B1 (FB1) - an 
inhibitor of the downstream ceramide synthase (CerS) - significantly increases in dSL 
formation by SPT4. Whether dSLs have a physiological role in lipid metabolism is not clear 
yet. Deoxy-ceramides were found as scaffold lipids facilitating lipid antigen presentation and 
suggesting a role in the innate immunity17. In a recent report, dSLs were demonstrated to 
accumulate together with ceramides upon TNFa stimulation18. However, the wt SPT forms 
dSLs only under certain conditions which argues for a regulatory mechanism allowing SPT to 
shift between L-serine and L-alanine utilization.  
A recent unbiased global proteomic approach revealed the presence of two phosphorylation 
sites (S384 and Y387) in the SPTLC2 subunit of SPT19. Both sites are in close proximity to 
the PLP binding motive (K379) and therefore good candidates to be involved in the regulation 
of SPT activity and substrate specificity. Here, we investigate whether a phosphorylation of 
S384 could act as a regulatory switch to shift substrate specificity of SPT between L-serine 
and its alternative substrate L-alanine. 
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Experimental Procedures 
 
Ethical approval for this study was obtained from the Joint Medical and Ethics Committee at 
the National Hospital for Neurology and Neurosurgery (NHNN). Written informed consent 
was obtained from all patients.  
 
Patients 
One hundred and seven patients with HSAN were selected from our inherited neuropathy 
database. The database includes patients seen in the peripheral neuropathy clinics in NHNN 
as well as patients whose DNA were referred from other hospitals for diagnostic and research 
testing.  All patients selected had a clinical diagnosis of HSAN, presenting with progressive 
distal sensory loss, with or without ulceromutilating complications or autonomic dysfunction. 
Because of the overlap between Charcot-Marie-Tooth Type 2B (CMT2B) and HSAN I, 
patients with motor involvement were included however, sensory features were always 
predominant. Diagnosis was based on clinical phenotype in addition to neurophysiology. All 
patients were negative for mutations in SPTLC1 and most were also negative for mutations in 
RAB7, NGFB, FAM134B and NTRK1. Four hundred and seventy-eight British control 
chromosomes were screened for the S384F mutation. 
 
Patient assessment 
All patients found to have mutations were seen and had detailed clinical and 
neurophysiological assessments performed, including assessment of neuropathy severity 
using the Charcot-Marie-Tooth Neuropathy Score 2 (CMTNS2)20. Nerve conduction studies 
were performed using standard techniques. 
 
Genetic sequencing 
All 12 exons and flanking introns of SPTLC2 were amplified using Roche polymerase chain 
reaction (PCR) reagents. Sequence reactions were performed using Big Dye Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems) and resolved on an ABI 3730xl Sequencer. See 
Supplementary Table 1 for primers and primer conditions. Sequence variants were confirmed 
by repeat sequencing. Three commonly used prediction programmes, PolyPhen2 
(http://genetics.bwh.harvard.edu/pph/), SIFT (http://blocks.fhcrc.org/sift/SIFT.html) and 
aGVGD (http://agvgd.iarc.fr/), were used to predict the effect of the mutations on protein 
function. 
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Cloning 
SPTLC2 cDNA was amplified by PCR from a cDNA library and cloned into a mammalian 
pcDNA 3.1D/V5-His-TOPO expression vector. The SPTLC2 mutations S384D, S384E, 
S384A, S384F, S384A+Y387F, Y387F and G382V were introduced by site-directed 
mutagenesis (primer sequences Supplementary Figure 2A). All constructs were verified by 
sequencing. 
 
Stable expression of mutant and wildtype SPTLC2 in HEK293 cells 
HEK293 cells (ATCC) were cultured in DMEM (Sigma-Aldrich) with 10% fetal calf serum 
(FisherScientific FSA15-043) and penicillin/streptomycin (100 U/ml and 0.1 mg/ml, 
respectively, Sigma-Aldrich). Stable transfection was performed using TurboFect (Thermo 
Scientific) under selection of 400μg/ml Geneticin (Gibco, Invitrogen). Expression of the 
constructs was confirmed by RT-PCR and immune blotting. 
 
2D-PAGE analysis 
Total proteins of CHO cells (grown for three days in Ham-F12 supplemented with 10% FCS) 
were extracted either in the presence or absence of a phosphatase-inhibitor cocktail (Roche). 
The aliquot without phosphatase inhibitor was treated with alkaline phosphatase (FastAP, 
Thermo Scientific) for 30min at 37°C. 1mg of total protein each was mixed with DeStreakTM 
Rehydration Solution (Amersham Biosciences) to a final volume of 100ul and loaded on a 
ImmobilineTM DryStrip (GE Healthcare), together with 0.5% IPG buffer (Amersham 
Biosciences) by passive rehydration over-night. Strip and buffer covered a pH ranged from 
pH 6-11. Iso-electric focusing was carried out on an Ettan IPGphor (Amersham Biosciences) 
according to following conditions: Step1: 300V, 200kVh; step 2: 1000V, 300kVh; step 3: 
5000V, 4500kVh; step 4: 5000V, 2000kVh; step 5: 500V, hold. All steps were performed at 
20°C, for 3hours with a maximal current of 50uA per strip. Focused proteins were 
subsequently equilibrated stepwise in 65mM DTT and 135mM iodacetamide (both in 1M 
Tris, 6M Urea, 30% v/v glycerol, 2% w/v SDS, 0.01% v/v bromphenolblue) with intermediate 
washing. Proteins were separated in the second dimension on a 12% SDS-PAGE, followed by 
western-blotting (PVDF membrane) and immunostaining using a polyclonal SPTLC2 
antibody 2 in 1:3000 dilution in 4% milk powder. 
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Cell-based SPT activity assay 
200 000 HEK293 cells stably transfected with the empty vector (control), SPTLC2wt and 
SPTLC2-mutants (S384D, S384E, S384F, S384A, S384A+Y387F, Y387F) were seeded and 
cultured as described above. After 3 days, the conditioned medium was exchanged with L-
serine and L-alanine deficient DMEM (Genaxxon BioScience). After a pre-incubation of two 
hours in this medium, isotope labeled (2,3,3)-d3 L-serine (1mM) together with 5mM 
(2,3,3,3)-d4 labeled L-alanine (Cambridge Isotope Laboratories, Inc.) were added to the cells 
(in some experiments (3C13)-labeled L-alanine was used instead as stated in the text). After 
24h or 48h (as stated in the text), the cells were washed twice with PBS, harvested and 
counted (Z2 Coulter Counter, Beckman Coulter). Cells were centrifuged (800xg, 5min at 4°C) 
and pellets were stored at -20°C for lipid extraction and analysis. The isotope labeled 
sphingoid bases are referred to as m+2 (from d3 L-serine) m+3 (from d4 L-alanine) or m+1 
(from 3C13 L-alanine). 
 
SPT activity assay in isolated proteins and lipid base extraction 
Total protein was extracted from frozen HEK293 cell pellets using SPT assay buffer (50mM 
HEPES pH8, 1mM EDTA, 0.2% Triton-X). 500ug total protein was added to a mix of 160uM 
palmitoyl-CoA (Sigma), 30uM pyridoxal-5'-phosphate (Sigma) and either 64mM L-serine or 
320mM L-alanine (Sigma). The mix was incubated for 45min at 37°C under constant shaking 
at 800 rpm (Thermomixer comfort, Eppendorf). SPT reaction was stopped by adding 500ul 
lipid extraction buffer containing 4 vol MetOH-KOH and 1 vol CHCl3 spiked with 200 pmol 
isotopic labeled d7-sphinganine and d7-sphingosine (Avanti Polar Lipids) as internal 
extraction standards. Lipids were base-extracted and analyzed on a TSQ Quantum Ultra MS 
analyzer (Thermo Scientific) as described earlier3.  
 
Kinetics with L-alanine 
400 000 HEK293 cells stable expressing SPTLC2wt or SPTLC2-S384D were cultured as 
described above. At day two, 0-35mM (2,3,3,3)-d4 labeled L-alanine (Sigma) diluted in PBS 
was added to the cells without changing the media. Cells were cultured for 48h, washed twice 
in PBS, harvested and counted (Z2 Coulter Counter, Beckman Coulter). Cells were 
centrifuged (800xg, 5min at 4°C) and pellets were stored at -20°C until lipid extraction and 
acid-base extraction.  
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Acid-base extraction and analysis of sphingoid bases 
500 ul MetOH including 200pmol internal standard (d7-sphinganine and d7-sphingosine, 
Avanti Polar Lipids) were added to 100ul of plasma or frozen cell pellets prior re-suspending 
in 100ul PBS. Lipid extraction was performed for 1hour at 37°C with constant agitation at 
1000 rpm (Thermomixer comfort, Eppendorf). Precipitated protein was removed by 
centrifugation for 5min at 16000xg and the supernatant was transferred to a new tube. Lipids 
were acid-hydrolysed (in 4.8% HCL final overnight at 65°C), neutralized by adding 1.5M 
KOH (final concentration) and were further extracted with chloroform (92.6% v/v) under 
basic conditions (0.15N NH4OH). Sphingoid bases were analyzed on a TSQ Quantum Ultra 
MS analyzer (Thermo Scientific) as described earlier3 with minor changes (see under analysis 
of ceramide species).  
 
Extraction and analysis of deoxy-ceramide and normal ceramide species 
For the ceramide and deoxy-dihydro-ceramide analysis, total sphingolipid extraction was 
done as before3, 21 with some modifications. In brief, cell pellet was re-suspended in 100 µl 
PBS. To this suspension, 1ml of methanol /chloroform (2:1) was added and spiked with 200 
pmol of the internal standard C12 ceramide (d18:1, 12:0). The mix was shaken in a thermo-
mixer at 37°C for 1 hour. Then, 0.5 ml of chloroform was added followed by 200 µl of 
alkaline water (500µl NH4OH (25%) in 250ml H2O and 20µl Bromphenol blue (2.5%). The 
mixture was centrifuged at 16100 g for 5 minutes. The upper phase was removed and the 
lower phase was washed three times with 1 ml alkaline water and dried under N2. Base 
hydrolysis using methanolic KOH was performed to remove the phospholipids. To the dried 
extracted lipids, 0.5 ml of methanolic -KOH: chloroform (4:1) was added and the mix was 
treated as mentioned in the first extraction step. The dried extracted lipids were stored at -
20°C until the LC/MS analysis was performed. 
The lipids were re-suspended in 100 µl methanol and then separated on a C18 column 
(Uptispere 120 Å, 5µm, 125 × 2 mm, Interchim, Montluçon, France)  with ammonium acetate 
(5mM) in water and methanol (1:1) as mobile phase A and methanol as the mobile phase B. 
The isocratic gradient was run as follows (22% mobile phase A, 78% mobile phase B for 20 
minutes then mobile phase B 100% for 25 minutes and then 22% mobile phase A, 78% 
mobile phase B for 5 minutes).  
The lipids were detected with an MS detector (TSQ Quantum Ultra, Thermo, Reinach, BL, 
Switzerland) using atmospheric pressure chemical ionization (APCI) as the ionization source. 
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Precursor ion scan was performed to identify ceramides with the fragment (m/z 264.3) and 
deoxy-dihydro-ceramides with (m/z 286.3) at 20mV collision energy. The (M+H)+ parent 
ions for each ceramide (d18:1,16:0 and d18:1,24:1) and deoxy-dihydro-ceramide (m18:0,16:0 
and m18:0,24:1) were quantified by normalizing the area under the peak to the internal 
standard and the protein concentration. Peak analysis and quantification was done in 
Xcalibur® (Thermo Scientific, Reinach, BL, Switzerland). 
 
Statistics 
One-way ANOVA was used for statistical analysis. Significance was further verified by 
Bonferroni multiple-correction.  P-values less than 0.001 were considered significant unless 
otherwise stated according to the following definition: ****p < 0.0001, ***p < 0.001, **p < 
0.01, *p < 0.05. Statistical analysis was performed using GraphPad Prism5. 
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Results 
Report of a novel HSAN I-causing mutation in the SPTLC2 subunit resides at the 
phospho-site Ser384 
In order to find novel SPT mutations associated with HSAN I, we sequenced the SPTLC2 
gene in 107 patients with HSAN I. In two unrelated index cases we identified a novel 
c.1151C>T (S384F) SPTLC2 variant. This variant was not present in 478 control 
chromosomes. Further studies showed that all affected members of these families who were 
tested also carried the mutation (Figure 1A).  
 
               
              
FIGURE 1A: Pedigree of two HSAN I families with S384F SPTLC2 mutation 
Square = male; circle = female; diagonal line = deceased; filled symbol = affected;  
m / + = heterozygous for mutation; arrow = proband; electropherogram of affected patients 
and control. Shown are two families A (III-2, III-8 and III-9) and B (II-1 and II-2). 
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The S384 residue is conserved in mammals but replaced by alanine in lower vertebrates 
(Figure 1B). PolyPhen2 and SIFT both predict that this change would be damaging. 
 
 
FIGURE 1B: Conservation of S384 and Y387 among species 
Multiple protein alignment of the SPTLC2 orthologous from human (Homo sapiens), mouse (mus 
musculus), rat (Rattus norwegicus), taurus (Bos Taurus), zebrafish (Danio rerio), fly (Drosophila 
melanogaster), baker’s yeast (Saccharomyces cerevisiae) and Candida albicans 
 
 
Clinical details 
The two S384F families could not be genealogically linked. Family A had clear autosomal 
dominant (AD) inheritance (Figure 1A). Clinical features are documented in Table 1. In 
comparison to other HSAN I families, patients from the two S384F families had a rather late 
onset of disease in the fourth or fifth decade. Most patients presented with reduced sensation 
in the feet with later development of motor weakness. Sensory loss occurred in a glove and 
stocking distribution; pinprick was affected to a greater extent than vibration perception, 
similarly to patients with SPTLC1 mutations 22. Sensory complications including ulcers and 
accidental burns occurred in all patients and some individuals had amputations. Motor 
involvement occurred in all families, though to a variable extent. The disease showed clinical 
heterogeneity even within families, e.g., III-8 having only mild distal lower limb weakness at 
65 years, while her sibling III-9 had significant proximal and distal upper and lower limb 
weakness and required a wheelchair since 65 years. None of the patients had significant 
autonomic symptoms. 
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Family Age 
last 
exam 
Sex AAO Symptoms at 
onset 
Positive 
sensory 
symptoms 
Motor  
UL / LL 
Sensory  Ulcers  Amputations Reflexes CMTNS2 
(CMTES2)  
Family A            
III-2 54 M Mid 30s Reduced 
sensation in feet 
Shooting 
pains 
N / N Pin to mid 
shin 
No No Preserved (6/28) 
III-8 65 F Early 40s Numbness in feet Shooting 
pains 
N / mild 
distal 
weakness 
Vib to ankle, 
Pin to wrist 
and above 
knee 
Yes BKA, toes Absent at 
ankle 
13/36 
III-9 71 M 40s Numbness in feet Shooting 
pains 
Mild 
proximal 
and severe 
distal UL 
and LL 
weakness 
Vib to costal 
margin, pin 
to face 
Yes No Absent in 
LL 
35/36 
Family B            
II-1 47 M 30s Pain in feet Shooting 
pains 
Mild distal 
UL 
weakness / 
N 
Vib to 
ankles, pin to 
elbows and 
above knee 
Yes BKA, Toes Absent at 
ankles 
19/36 
II-2 45 M 33 Numb feet Shooting 
pains 
N / N Vib to 
ankles, pin to 
mid-palm 
and below 
knees 
Yes No Preserved  ND 
TABLE 1: Clinical details of SPTLC2 S384F patients  
AAO = age at onset; UL = upper limbs; LL = lower limbs; CMTNS2 = Charcot-Marie-Tooth Neuropathy Score version 2 20; CMTES2 = CMT 
Examination Score, a subset of the CMTNS2; M = male; F = female; N = normal; ND =  not done; Vib = vibration; BKA = below knee amputation 
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Neurophysiology 
Details of the neurophysiology from the S384F patients are shown in Supplemental Table 2. 
Overall, nerve conduction studies demonstrated a sensorimotor axonal neuropathy. Sensory 
action potentials were absent in the lower limbs and reduced or absent in the upper limbs. 
Motor responses were absent or reduced in the lower limbs and normal or reduced amplitude 
in the upper limbs. Motor conduction velocity ranged from normal (>50 m/s) to within the 
demyelinating range (<38 m/s) similar to what is seen in our families with SPTLC1 
mutations23. 
 
Plasma sphingoid- and deoxy-sphingoid base levels  
The composition of plasma sphingolipids was analyzed in four S384F patients and compared 
to plasma from three random HSAN I patients with a C133W mutation and two healthy 
controls (Figure 2A+B). Total sphingolipid plasma levels were not different for S384F and 
C133W carriers, compared to healthy controls (Figure 2A). In contrast, total dSL levels 
(deoxySO+deoxySA) were significantly higher in the plasma of patients with the S384F 
mutation (Figure 2B). The dSL plasma levels in S384F carriers were comparable to those 
with the C133W mutation and ranged from 1.5-5uM.  
 
A:          B: 
        
FIGURE 2: Clinical characterization of the novel HSAN I mutation S384F 
Total lipids from plasma of four S384F and three C133W patients were extracted and total sphingoid-
(A) and deoxy-sphingoid base (B) levels analyzed after acid-base hydrolysis. All carriers of the S384F 
as well as the C133W mutations had significant elevated deoxy-sphingoid base levels without 
differences in their normal sphingoid base contents compared to healthy controls. Data are shown as 
mean, with error bars representing standard deviations.  Error bars and standard deviation were 
calculated using 1-way ANOVA followed by Bonferroni's Multiple Comparison Test with ****p < 
0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.  
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SPTLC2 is phosphorylated in vivo 
In an unbiased global phospho-proteomic approach Olsen et al. found two phosphorylation 
sites (S384 and Y387)  in the SPTLC2 subunit of SPT19. A posttranslational modification of 
SPTLC2 was confirmed by 2D-PAGE and western blot in a CHO cell extract. The isoelectric 
focusing revealed a typical punctuated migration pattern for SPTLC2 (Figure 3, left panel) 
which was reduced to a single spot upon treatment with alkaline phosphatase (Figure 3, right 
panel).  
 
FIGURE 3: SPTLC2 phosphorylation pattern is lost after phosphatase treatment  
Total proteins of CHO cells (grown for three days in Ham-F12 supplemented with 10% FCS) were 
extracted in the presence of phosphatase-inhibitors (left panel) or treated with alkaline phosphatase 
(right panel).  The extract was subjected to iso-electrical focusing in the first dimension and separated 
on a 12% SDS-PAGE in the second dimension. SPTLC2 was detected with a polyclonal antiSPTLC2 
antibody. 
 
Effect of a constitutive phosphorylated and un-phosphorylated SPTLC2 on SPT activity 
To investigate the influence of the two putative phosphorylation sites S384 and Y387 on SPT 
activity and substrate specificity we created a set of mutants which either mimicked a 
constitutively phosphorylated (S384D, S384E) or an un-phosphorylated state of the enzyme 
(S384A, Y387F, S384A+Y387F). The phosphorylation at Y387 could not be mimicked. The 
mutant SPTLC2 subunits were stably expressed in HEK293 cells and expression levels were 
similar for mRNA and protein (Supplemental Figure 2B+C).  
HEK cells expressing the wtSPTLC2 subunit also revealed a typical phosphorylation pattern 
after isoelectric focusing (Supplemental Figure 4A) that is different in the mutants where the 
two phosphosites were knocked-out ( S384A and Y387F, Supplemental Figure 4B+C).  
We analyzed the effect of the mutations on SPT activity in transfected HEK293 cells. In 
isolated proteins the canonical activity of the phosphorylation mimicking mutants (S384D and 
S384E) was 50-60% reduced, but was not different in the negative mutants S384A, Y387F or 
S384A+Y387F compared to the wild type (Figure 4A). With L-alanine we observed a 2.5 fold 
increased activity in the S384D mutant but not for the homologous S384E variant or the 
negative mutants S384A, Y387F, S384A+Y387F (Figure 4B). These results were compared 
to a  previously reported SPTLC2 HSAN I mutation (G382V)12  which is located in close 
proximity to the identified two phospho-sites. In a cell-free environment, the G382V mutant 
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showed a 70% decreased activity with L-serine (Figure 4A) but no significant activity with L-
alanine (Figure 4B) although increased dSL formation was previously found in G282V 
expressing HEK293 cells and in lymphoblasts of G382V carriers12. However, the levels of 
deoxySA that have been produced in cells during culture, were elevated in both, S384D and 
G382V expressing cells, but not in SPTLC2wt or S384A, Y387F and S384A+Y387F (Figure 
4C). This indicates that SPT shows distinct activities when measured in isolated proteins or 
living cells.  
 
A:      B: 
   
C: 
    
FIGURE 4: Activity of SPTLC2 phosphomutants in isolated proteins 
SPT Activity was analyzed in isolated proteins extracted from HEK293 cells stably transfected with 
either wildtype SPTLC2 or the SPTLC2 mutants S384D, S384E, S384A, Y387F, S384A+Y384F and 
G382V. The activity in cell-free conditions was determined in the presence of (A) L-serine or (B) L-
alanine. (C) DeoxySA levels (non-acylated) in cells expressing either SPTLC2wt or the mutants 
S384D, S384E, S384A, Y387F, S384A+Y384F and G382V. All data are shown as mean, with error 
bars representing standard deviations.  Error bars and standard deviation were calculated using 1-way 
ANOVA followed by Bonferroni's Multiple Comparison Test with ****p < 0.0001, ***p < 0.001, **p 
< 0.01, *p < 0.05.  
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We therefore performed a metabolic labeling assay with SPTLC2wt or mutant expressing 
HEK293 cells to analyze the mutant’s activity in intact cells. Cells were cultured in the 
presence of isotope labeled (d3) L-serine and (d4) L-alanine which resulted in the formation 
of (m+2) SA and (m+2) SO or (m+3) deoxySA, respectively since one of the deuteriums is 
lost during the SPT condensation reaction24. Like in cell-free conditions, we observed a 2-3 
fold higher dSL formation in the S384D cells but not in cells expressing the homolog S384E 
or the negative mutants (S384A, Y387F and S384A+Y387F) (Figure 5A). Although we 
observed a reduced activity with L-serine for the S384D and S384E mutant in isolated 
proteins (Figure 4A) we did not see any reduced formation of (m+2) SO and (m+2) SA in 
living cells (Figure 5B). Analysis of the lipid species revealed that ceramides were mostly 
present as d18:1;16:0 and d18:1;24:1 (Figure 5C) whereas deoxy-ceramides were conjugated 
to the same fatty acids but primarily found in the dihydro-form, m18:0;16:0 and m18:0;24:1 
(Figure 5D). S384D expressing cells had significantly higher total deoxy-dihydro-ceramide 
levels than cells expressing the S384E or the negative mutants (Figure 5D).  
 
A:       B: 
     
C:       D: 
 
FIGURE 5: Activity of SPTLC2 phosphomutants in HEK cells 
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SPT Activity was analyzed in intact HEK293 cells which were stably transfected with either wildtype 
SPTLC2 or the SPTLC2 mutants S384D, S384E, S384A, Y387F, S384A+Y384F and G382V.  
(A+B) Incorporation of isotope labeled (2,3,3)-d3 L-serine (1mM) and (2,3,3,3)-d4 labeled L-alanine 
(5mM) within 24h. The extracted lipids were subjected to an acid-base hydrolysis as described in 
experimental procedure and the free isotope labeled sphingoid bases analyzed LC-MS. The resulting 
sphingoid bases originating from d3 L-serine and d4 L-alanine are referred to as (m+2) and (m+3) 
respectively.  
(C+D) Total lipids were extracted from SPTLC2wt and mutants expressing cells and ceramide (C) and 
deoxy-ceramide species (D) analyzed by LC-MS. All data are shown as mean, with error bars 
representing standard deviations.  Error bars and standard deviation were calculated using 1-way 
ANOVA followed by Bonferroni's Multiple Comparison Test with ****p < 0.0001, ***p < 0.001, **p 
< 0.01, *p < 0.05.  
 
 
Increasing concentrations of (d4)-L-alanine in the medium elevated dSL formation only in 
S384D expressing cells, but not in SPTLC2wt cells (Figure 6). This shows that formation of 
dSLs in the wt SPT is not directly associated with any increased supply of alanine.  
 
 
FIGURE 6: L-alanine kinetics in wt SPTLC2 and phosphorylation mimicking mutant 
S384D 
Deoxy-sphingolipid formation in response to increasing amounts of d4 L-alanine in the medium of 
SPTLC2wt and S384D expressing cells. Cells were cultured in the presence of d4 L-alanine (0-35mM) 
for 48h. After harvesting the cells the total lipids were extracted and the sphingoid base profile 
analyzed by LC-MS after acid-base hydrolysis. The sphingoid bases were quantified relative to the 
internal extraction standards (d7 SO and d7 SA). The graph shows the sum of labeled (m+3) deoxySA 
and (m+3) deoxySO. 
 
 
Effect of the HSAN I associated SPTLC2-S384F mutation on SPT activity  
The HSAN I-causing S384F mutation led to a decreased activity with L-serine and an 
increased activity with L-alanine in a cell-free environment that was similar to the S384D 
mutant (Figure 7A). However, the metabolic labeling assay in intact cells did not reveal any 
reduced formation of (m+2) SO and (m+2) SA (Figure 7B) but a significantly increased dSL 
formation which was even 2-3 fold higher compared to the S384D mutation (Figure 7C). Like 
wt SPTLC2 protein, the mutant SPTLC2 variants (S384D, S383E, S384A, Y387F, 
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S384A+Y387F) co-localized with the ER marker calnexin, rendering it unlikely that 
mislocation is leading to the observed differences in SPT activity (Supplemental Figure 5). 
 
A:       
 
B:      C: 
  
FIGURE 7: Biochemical characterization of the novel HSAN I mutation 
SPT activity was analyzed in a cell-free environment (A) and in intact HEK293 cells (B+C) which 
were stably transfected with SPTLC2 (wt), the phosphorylation mimicking S384D or the SPTLC2-
HSAN I associated mutation S384F. (A) Activity in isolated proteins was determined in the presence 
of L-serine or L-alanine. S384F and S384D both showed a decrease for L-serine activity and an 
increase for L-alanine activity. Free sphingoid bases were quantified relative to internal extraction 
standards (d7SO and d7SA). Shown is the ratio of keto-deoxySA/keto-SA per min.  
B+C) Cells were grown in DMEM lacking L-serine, supplemented with isotope labeled (2,3,3)-d3 L-
serine (1mM) together with 5mM (3C13)- labeled L-alanine and incubated for 48h. Lipids were 
extracted, acid-base hydrolysed and analyzed using LC-MS. Sphingoid bases were quantified relative 
to internal extraction standards (d7 SO and d7 SA). The resulting sphingoid bases are referred to m+2 
for d3 L-serine and m+1for 3C13 L-alanine (B). m+2 sphingoid base levels were not different in the 
analyzed mutants compared to the wt (C).  
Data are shown as mean, with error bars representing standard deviations.  Error bars and standard 
deviation were calculated using 1-way ANOVA followed by Bonferroni's Multiple Comparison Test 
with ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.  
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Discussion  
Elevated dSL levels are a hallmark for the inherited neuropathy HSAN I5-12 which is caused 
by several mutations in SPT. Low levels of dSLs are also present in the plasma of healthy 
individuals and have been shown to increase in metabolic disorders like the metabolic 
syndrome or diabetes14-16. Thus, not only the mutated but also the wt SPT is capable to form 
dSLs. However, an increased availability of L-alanine does not automatically lead to 
increased dSL formation which shows that these lipids are not simply formed as by-products 
of the canonical SPT reaction (Figure 6). This indicated that additional factors are required to 
induce a shift in substrate specificity in the wildtype enzyme.  
In a screen for novel HSAN I mutations in SPT, we identified a new SPTLC2-S384F variant 
in two unrelated HSAN I families. In line with previously reported HSAN I mutations5-12 this 
variant was associated with increased dSL plasma levels in the four patients. Their plasma 
levels were comparable to previously reported HSAN I mutations (e.g. SPTLC1-C133W). 
Clinically, the S384F mutation is associated with a “classical” HSAN I phenotype primarily 
affecting sensory- and to a lower extent also motor functions. However, as for other HSAN I 
mutations, there is considerable clinical heterogeneity between the patients even from the 
same family.  
Interestingly, an unbiased systematic approach to characterize the phospho-proteome in EGF 
stimulated HeLa cells revealed that S384 together with Y387 in SPTLC2 are modified by 
phosphorylation. The consequence of this SPTLC2 phosphorylation was not investigated by 
the authors in detail but was shown to be independent to the EGF stimulus and did not follow 
a kinetic pattern19. Isoelectric focusing revealed a significant heterogeneity in the isoelectric 
point (pI) for the SPTLC2 subunit (Figure 3, Supplemental Figure 4A). This heterogeneity 
was lost after alkaline phosphatase treatment which further supports the concept of a 
phosphorylated SPTLC2. The two identified residues, S384 and Y387, are located in close 
proximity to the PLP binding motive and are thereby well positioned for being involved in 
regulating enzyme activity.  
We therefore investigated the putative regulatory role of these sites on SPT activity by 
creating a set of mutants which mimicked either a constitutively phosphorylated (S384D, 
S384E) or non-phosphorylated (S384A, Y387F, S384A+Y387F) protein. In isolated proteins, 
the S384D and S384E mutant showed reduced activity with L-serine and only the S384D and 
not the homologue S384E mutant revealed increased activity with L-alanine. Likewise, a 
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reduced activity with L-serine and an increased activity with alanine were observed in the 
novel HSAN I-causing S384F mutation but not in those mutants that mimicked a non-
phosphorylated state of the enzyme (S384A, Y387F, S384A+Y387F). This indicates that the 
switch between L-serine and L-alanine activity requires specific structural conditions at S384 
and is not caused by a general or arbitrary amino acid exchange at this position. As a 
limitation, we could not investigate the effect of a phosphorylation at Y387. These results 
were confirmed in living cells by a metabolic labeling assay using isotope labeled L-serine 
and L-alanine. Again, dSL formation was increased in S384D and S384F expressing cells but 
not in the S384E or the negative mutants.  
We noticed differences in SPT activity when analyzed in isolated proteins and in living cells. 
In detail, we observed a decreased canonical activity for the S384D, S384E, S384F and 
G382V mutant in isolated proteins but the analysis in living cells revealed no differences in 
the formation of serine based sphingoid bases (sphingosine and sphinganine). These, at first 
sight contradictory results might be explained by the influence of several factors which were 
reported to control SPT activity and de novo sphingolipid synthesis. Recent reports showed 
that sphingolipid de novo production is tightly controlled by a group of small proteins 
(ORMDL1, 2 and 3) to prevent a harmful overproduction of sphingolipids by SPT. The ORM 
proteins act as negative regulators and inhibit SPT activity in response to elevated cellular 
sphingolipid levels25-27. In yeast un-phosphorylated ORM proteins bind to SPT and inhibit 
sphingolipid de novo formation27. In case of a sphingolipid deficiency, the ORM proteins are 
phosphorylated, dissociate from the SPT complex and activate de novo synthesis by SPT. In 
addition,  two other small proteins (ssSPTa and b) have been reported to regulate the overall 
SPT activity and specificity for certain acyl-CoAs 28.  
It is important to note that de novo synthesis is not the only route for a cell to generate 
sphingolipids. The cell can metabolize sphingolipids also from external sources for example 
from lipoproteins in the culture medium and it is likely that de novo synthesis by SPT is down 
regulated if the availability of exogenous sphingolipids from the medium is sufficient. This 
prevents any toxic overproduction of ceramides which will lead to apoptosis. The concept that 
cellular de novo generation of sphingolipids is essentially suppressed in case of a sufficient 
sphingolipid supply, might explain why we did not see differences in the incorporation of 
isotope labeled L-serine between SPTLC2 wt and S384D/E/F expressing cells, although the 
activity in isolated proteins is significantly reduced in these mutants. Under the condition of 
down regulated sphingolipid de novo synthesis, the reduced total activity of the mutants might 
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not be a limiting factor anymore. Consequently, the alternative SPT activity with L-alanine is 
independent of this regulation, since the activity pattern of the mutants with alanine was the 
same in isolated proteins and intact cells.  
However, the regulatory mechanism underlying the shift in substrate specificity and dSL 
formation for wt SPT is not known. Our data suggest that phosphorylation of SPTLC2 at 
S384 can shift the activity of the enzyme towards the use of L-alanine. This shift might be 
either caused by structural changes in the active site, or by binding of additional factors to the 
SPT enzyme. Notably, an increased activity with L-alanine was only seen in the S384D but 
not for the homolog S384E mutation although aspartate (D) and glutamate (E) are structural 
homologues and differ only by one methyl-group in length. This indicates that the switch in 
activity between serine and alanine requires specific structural changes and is not caused by 
any mutation at this position. Interestingly, a closely located HSAN I mutation (G382V) did 
not show any increased dSL formation in a cell-free environment, although an elevated dSL 
formation was shown in G382V expressing HEK293 cells and also in lymphoblasts of G382V 
carriers12. The difference in cell-free conditions compared to intact cells was also observed for 
other HSAN I mutants (discussed in the general conclusions section) and suggests that other 
cellular factors contribute to the substrate specificity of SPT.  
Earlier data from our group suggested that the active mammalian SPT is an octamer with a 
mass of about 460kD and probably composed of four heterodimers each formed by one 
SPTLC1 and either an SPTLC2 or SPTLC3 subunit 29, 30. Unfortunately, the x-ray structure 
for the mammalian SPT is not re-solved yet. However, the molecular structure of the 
prokaryotic SPT is re-solved from two sphingolipid generating bacteria, Sphingomonas 
paucimobilis and Sphingobacterium multivorum22, 31. In contrast to the mammalian enzyme, 
the prokaryotic SPT is a homodimer and either soluble (S. paucimobilis) or loosely attached 
to the inner cell membrane (S. multivorum)32. The PLP binding motif (FTKSXXXXSer384G) in 
the x-ray structure from S. multivorum (PDB ID: 3A2B) is organized as a coil surrounded by 
two beta-sheets (Supplemental Figure 3A). Modeling the mammalian sites S384 and Y387 
into this structure indicates that Ser384 is positioned directly in the core of the PLP binding 
motif, pointing outside towards the PLP-binding pocket whereas Y387 is localized on the 
beta-sheet and pointing away from the binding pocket (Supplemental Figure 3B). This 
indicates that residue S384 rather than Y387 could be accessible for a kinase from outside.  
Like the S384D, also the HSAN I associated S384F variant shows increased dSL formation in 
isolated proteins. Although phenylalanine is a non-charged amino acid, the bulky aromatic 
Chapter 2 
 
 65
side group might mimic similar structural changes as a phosphorylated S384. Although the 
activity with L-alanine in isolated proteins was similar for the S384D and S384F, the latter 
showed a 2-3-fold higher dSL formation in the metabolic labeling assay in living cells. This 
again indicates that additional factors influence the cellular activity of SPT with L-alanine.  
In addition to their suggested neurotoxicity in HSAN I, dSLs are not yet known to exert any 
physiological function. The finding that a specific phosphorylation in SPT could act as a 
molecular switch to shift the substrate specificity of the enzyme from L-serine to L-alanine 
further supports the idea for a specific physiological function of dSLs in cellular lipid 
metabolism. However, the exact function, underlying regulatory mechanisms and associated 
signaling pathways remain subjects for future studies. 
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Footnotes 
This work was supported by the Gebert Rüf Stiftung. 
Supplemental Information  
I. FIGURES 
 
 
SUPPLEMENTAL FIGURE 1: Pathway illustration of sphingolipid de novo synthesis 
with L-serine and L-alanine aminoacid substrate 
  
Chapter 2 
 
 67
S384D_fw:5’-TCA CAA AGA GTT TTG GTG CTG ATG GAG GAT ATA TTG GAG GC-3’  
S384D_rv:5’-GCC TCC AAT ATA TCC TCC ATC AGC ACC AAA ACT CTT TGT GA-3’  
 
S384E_fw:5’-TTC ACA AAG AGT TTT GGT GCT GAG GGA GGA TAT ATT GGA GGC AAG-3’  
S384E_rv:5’-CTT GCC TCC AAT ATA TCC TCC CTC AGC ACC AAA ACT CTT TGT GAA-3’  
 
S384F_fw:5’-CAA AGA GTT TTG GTG CTT TCG GAG GAT ATA TTG GAG GC-3’ 
S384F_rv:5’-GCC TCC AAT ATA TCC TCC GAA AGC ACC AAA ACT CTT TG-3’ 
 
S384A_fw:5’-CAC AAA GAG TTT TGG TGC TGC AGG AGG ATA TAT TGG AGG CA-3’ 
S384A_rv:5’-TGC CTC CAA TAT ATC CTC CTG CAG CAC CAA AAC TCT TTG TG-3’ 
 
S384A+Y387F_fw:5’-CAA AGA GTT TTG GTG CTG CTG GTG GAT TTA TTG GAG GCA AGA AGG-3’  
S384A+Y387F_rv:5’-CCT TCT TGC CTC CAA TAA ATC CAC CAG CAG CAC CAA AAC TCT TTG-3’  
 
Y387F_fw: 5’-GAG TTT TGG TGC TTC TGG TGG ATT TAT TGG AGG CAA GAA GG-3’  
Y387F_rv:5’-CCT TCT TGC CTC CAA TAA ATC CAC CAG AAG CAC CAA AAC TC-3’  
 
G382V_fw:5’-GAA CGT TCA CAA AGA GTT TTG TTG CTT CTG GAG GAT ATA TTG G-3’  
G382V_rv:5’-CCA ATA TAT CCT CCA GAA GCA ACA AAA CTC TTT GTG AAC GTT C-3’  
 
SUPPLEMENTAL FIGURE 2A: Primer pairs for site-directed mutagenesis in SPTLC2 
 
 
SUPPLEMENTAL FIGURE 2B: Protein expression control of the stable transfected 
HEK293 mutants 
Expression levels of wild type SPTLC2 and the SPTLC2 mutants in stably transfected HEK293 cells. 
The proteins were separated on a 12% SDS Page and detected by a V5-tag antibody (higher bands). 
Beta-actin was used as the loading control (lower bands).  
 
 
 
 
SUPPLEMENTAL FIGURE 2C: SPTLC2 mRNA 
levels in the HEK293 mutants 
mRNA expression of wild type SPTLC2 and the 
SPTLC2 mutants in stably transfected HEK293 cells. 
Expression levels of GAPDH were used for 
normalization. 
empty SPTLC2 -S384D -S384E -S384F -S384A -Y387F -S384A
Y387F
-G382V
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SUPPLEMENTAL FIGURE 3A: 
Structure of SPT in sphingobacterium 
multivorum (PDB:3A2B) 
SPT structure of S. multivorum was illustrated 
using UCSF Chimera 1.6.2.  
Lys244 (Lys379) in red and Leu249 (Ser384) 
in orange are located in the coil structure 
surrounded by 2 beta-sheets whereas the 
second phosphosite Phe252 (Tyr387) in 
orange is found on the beta-sheet outside the 
PLP-binding motif sequence. Other 
aminoacids located on the coil structure are 
illustrated in turquois (Ser248, Ala247, 
Leu246, Ser245, Ser243, Phe242). The 
substrate (serine-PLP) is bound to Lys244 
(purple-pink). His138 and His213 (blue) are 
important for coordinating the right position 
of the substrate. 
 
 
 
 
SUPPLEMENTAL FIGURE 3B: 
Structural modeling of SPTLC2 
phosphosites in sphingobacterium 
multivorum  
The sequence of the mammalian SPTLC2 
subunit was modeled into the protein structure 
of S. multivorum (PDB:3A2B) using SWISS-
MODEL (http://swissmodel.expasy.org). 
The results are illustrated using USCF 
Chimera 1.6.2. Both phosphosites (Ser384 
and Tyr387) are shown in orange and the 
Schiff-base forming Lys379 in red. Lys379 
and Ser384 are both located on the coil 
structure of the inner core of the PLP-binding 
motif (FTKSXXXXSerG) whereas the second 
phosphosites Tyr387 is located on the beta-
sheet. 
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A: SPTLC2wt  
Endogenous and transfected protein 
 
 
B: SPTLC2-S384A           C: SPTLC2-Y387F 
Endogenous and transfected mutant protein        Endogenous and transfected mutant protein 
      
 
D: SPTLC2-S384A          E: SPTLC2-Y387F 
Only transfected mutant protein       Only transfected mutant protein 
       
SUPPLEMENTAL FIGURE 4: 2D-gel analysis of the HEK293 phospho-mutants 
HEK293 cells expressing wt (SPTLC2) and mutant-SPTLC2 (S384A, Y387F) were analyzed on a 2D-
gel. Endogenous and transfected SPTLC2 were detected using a polyclonal antibody2 (1:3000) 
whereas the use of an anti-V5-antibody 1:2000 (Serotec) allows exclusively detection of the 
transfected SPTLC2 variants. The wt (SPTLC2) transfected HEK cells revealed a phosphorylation 
pattern (A), that is changed in the HEK cells expressing the mutated SPTLC2 (B-E) suggesting that 
the phosphorylation sites are lost in the mutants.  
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HEK-empty 
    
HEK-SPTLC2 
    
HEK-SPTLC2_S384D 
  
HEK-SPTLC2_S384E 
     
HEK-SPTLC2_S384A 
     
HEK-SPTLC2_S384F 
           
HEK-SPTLC2_Y387F 
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HEK-SPTLC2_S384A_Y387F 
        
 
SUPPLEMENTAL FIGURE 5: Co-localization of transfected wt and mutant SPTLC2 
variants with ER marker calnexin in HEK293 
Localisation of transfected vector (empty), wt (SPTLC2) and mutant-SPTLC2 (S384D, S384E, 
S384A, Y387F, S384A+Y387F) was analyzed in HEK293 cells revealed co-localisation of all variants 
with the ER marker calnexin (blue DAPI; green calnexin; red SPTLC2 variants. HEK293 cells were 
cultured in chamber culture slides (BD Falcon) to 50% confluence and fixed in 4% paraformaldehyde 
for 15min at 37°C. Permeabilization was performed for 5min using ice-cold acetone.  Cells were 
washed in double-distilled water and dried for some seconds. Unspecific binding sites were blocked 
with 1% horse serum in PBS for 30min. After washing in PBS, mouse anti-V5-tag antibody diluted 
1:2000 (Serotec) in blocking solution together with rabbit anti-calnexin antibody 1:4000 (Sigma) were 
incubated for 2 hours. After 2 times washing in PBS, Alexa Fluor 594 conjugated secondary goat anti-
mouse antibody (Invitrogen) diluted 1:1000 in blocking solution was incubated together with 30nM 
DAPI for 1 hour in the dark. Immunofluorescence of the V5 tagged SPTLC2 mutant and wildtype 
protein, calnexin and nuclein acid were detected with Zeiss Axiovert 200M using AxioVision 4 
software 
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II. TABLES 
 
 
 
 
 
 
 
 
 
 
 
 
SUPPLEMENTAL TABLE 1: Primer pairs for sequencing SPTLC2 
PCR comprised the following steps for all exons except exons 1 and 5: 1) 95°C for 15 minutes, 2) 25 cycles of 95°C for 30 seconds, 60°C (reduced by 0.4°C per cycle) for 30 
seconds, and 72°C for 45 seconds, 3) 13 cycles of 95°C for 30 seconds, 50°C for 30 seconds, and 72°C for 45 seconds, 4) 72°C for 10 minutes. 
For exon 1: 1) 95°C for 15 minutes, 2) 38 cycles of 95°C for 30 seconds, 58°C (reduced by 0.4°C per cycle) for 30 seconds, and 72°C for 45 seconds, 3) 72°C for 10 minutes. 
10% DMSO 
For exon 5: 1) 95°C for 15 minutes, 2) 37 cycles of 95°C for 30 seconds, 51.3°C (reduced by 0.4°C per cycle) for 30 seconds, and 72°C for 45 seconds, 3) 72°C for 10 minutes. 
 
Patient Median Ulnar Radial Common peroneal Posterior tibial Superficial 
peroneal 
Sural 
 DML 
ms 
CV 
m/s
CMA
P mV 
SAP 
uV 
DM
L 
ms 
CV 
m/s 
CMA
P mV 
SAP 
uV 
SAP 
uV 
DML 
ms 
CV 
m/s 
CMA
P mV
DM
L 
ms 
CV 
m/s 
CMAP 
mV 
SAP uV SAP uV 
A II-6 5.3 42  NR 6 28  NR          
 A III-8 3.0 58 7.0 NR 2.9  8.7 NR 13 NR      NR NR 
A III-9 NR   NR NR   NR NR NR        
B II-1 3.9 49 6.1 NR 2.5 46 2.5 NR 2 3.5 42 3.3      
B II-2 3.7 50 8.6 7 3.2 56 9.4 2 21 NR   NR   NR NR 
SUPPLEMENTAL TABLE 2: Nerve conduction studies in SPTLC2 S384F patients  
DML = distal motor latency; CV = conduction velocity; CMAP = compound motor action potential; SAP = sensory action potential; ms = milliseconds; m/s = 
metres per second; mV = millivolts; uV = microvolts. Shown are members of the two families A (III-2, III-8, III-9) and B (II-1, II-2) 
SPTLC2 exon Forward primer Reverse primer Primer conditions 
1 CCTACAGAGCCTGCCTTG CGGTGTGGACTGGCGGAG 58 touchdown 
2 GGTATAATTCAGCAAATCTC TTTAACTGCATCTGGAATAG 60-50 touchdown 
3 TAATGAAATTGCCCTTATAC AATCATATTGTATCCTCAGC 60-50 touchdown 
4 ATAGACTTTGTTCTCTCTGC CTAAATGACATGACAAAGTG 60-50 touchdown 
5 TCTGAAAAGGACACAACAC TTTAGCTCACTCTGACTGC 51.3 
6 AGCTATTAGTGTTTGTGGC TCATTTATACTTTCAAGTGC 60-50 touchdown 
7 TATCTGAGGCATGGTTTC TAGACTAATGTTCCCTTCAG 65-55 touchdown 
8 ATAATAATGAAGTGCCAAAC GTATTATGAGCCTAAACCAG 60-50 touchdown 
9 TCTAGAACTTAGAAGGAAAGG TGCCTATTAGTAAACCTGAC 60-50 touchdown 
10 GATAGAATGGAGATAGAGGAG TAAGGACAAGACCATTTTC 60-50 touchdown 
11 TTGAAATCTTTGAGGACAG GCTCACAAGAACATCAAG 60-50 touchdown 
12 GCACTAGACATAAGTCCTGC ACAGAAGTGTGGTTCCTG 60-50 touchdown 
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Summary  
Background: 1-Deoxy-sphingolipids (dSLs) are an atypical class of sphingolipids that were 
found to accumulate in the plasma of patients with the rare inherited neuropathy HSAN I 
(Hereditary neuropathy type I) which is caused by several missense mutations in serine 
palmitoyltransferase. Plasma from healthy individuals also contains low but detectable dSL 
levels which are increased in patients with certain metabolic disorders (metabolic syndrome, 
diabetes type 2). Very little is known about the factors that are involved in the generation and 
downstream processing of these atypical lipids.  
Results: Sphingoid base profiling of several commonly used cell lines revealed high dSL 
levels in the macrophage cell line RAW264.7 as well as in HEK293 cells. Monocytic cell 
lines like THP1 or HL60 did not show dSL formation to the same extent. We therefore 
investigated the change in the sphingoid base profile in THP1 cells during PMA stimulated 
monocyte to macrophage differentiation with the aim to identify metabolic factors that 
regulate dSL formation. Upon differentiation, THP1 cells increasingly generated dSLs at the 
expense of  forming sphinganine- the canonical SPT product. The increase in dSL generation 
was accompanied by an increase in intracellular alanine concentration whereas the serine 
concentration did not alter over the period of differentiation. The SPT protein expression 
profiles changed in a manner that correlated temporally with the dSL formation and 
intracellular alanine concentration. We observed a conversion of deoxySA to deoxy-ceramide 
(by the appearance of deoxySO backbones) even in the presence of the CerS inhibitor 
Fumonisin B1. Furthermore, the formation of deoxySO (and deoxySO containing 
sphingolipids) -but not of deoxySA (and deoxySA containing sphingolipids) - was dependent 
on the presence of PMA. The PMA dependant deoxySO generation was further stimulated in 
the presence of FB1. This activity pattern was shown to be specific in THP1 monocytes since 
the addition of PMA to HEK293 cells resulted in the opposite effect and rather inhibited dSL 
generation. Increased dSL formation during differentiation was confirmed in  human primary 
monocytes. 
Conclusion: We showed that dSL formation is a coordinated process during monocyte to 
macrophage differentiation. The metabolism of dSLs is influenced by PMA and FB1, both 
known activators of PKC and correlates with intracellular changes in the amino acid 
metabolism. Our results indicate that the formation of dSLs is of physiological relevance 
during monocyte to macrophage differentiation. 
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Introduction  
The first step of sphingolipid de novo biosynthesis is the condensation of L-serine and 
palmitoyl-CoA. This reaction is catalyzed by serine palmitoyltransferase (SPT) in a pyridoxal 
5’phosphate dependent manner1. SPT consists of three subunits, SPTLC1/2/3 together with 
small SPT subunits, ssSPTa/b that were reported to modulate SPT activity and the acyl-CoA 
substrate specificity1-3. The overall SPT complex composition is not known yet but was 
suggested to consist of a functional heterodimer of SPTLC1 together with SPTLC2/3 in 
combination with the small SPT subunits (ssSPTa/b) and to be organized in a higher mass 
complex2-4. Besides the canonical L-serine substrate, SPT can also use L-alanine and L-
glycine to a certain extent which results in the formation of 1-deoxy-sphingolipids (dSLs)5, 6.  
Assuming that dSLs are metabolized in the same way as the serine-derived sphingolipids, 
their further processing requires N-acylation, a reaction that is catalysed by a ceramide 
synthase isoform (CerS) and results in deoxy-dihydro-ceramides.  A desaturase (DES) 
introduces a C4 double-bond into the deoxy-sphinganine backbone leading to the unsaturated 
deoxy-ceramide. During degradation the N-acyl chain is removed by the action of a 
ceramidase, resulting in the free deoxy-sphingosine (deoxySO); (see Figure 1A). So far, it 
was shown that dSLs are acylated to deoxy-dihydro-ceramides 6, but their further downstream 
metabolism remains unknown. As dSLs lack the C1-hydroxyl group, they can neither be 
metabolized to complex sphingolipids nor degraded by the canonical catabolic pathway.  
Deoxy-sphingolipids were reported to be generated in cells during longer culture periods and 
in response to Fumonisin B1, a mycotoxin and inhibitor of CerS 5-8. Besides, dSL levels were 
described to increase together with ceramides in response to TNF treatment in dopaminergic 
neurons. Here, they reduced the cell viability in a dose-dependent manner and inhibited 
neurite outgrowth and branching in cultured DRG neurons 9. In addition, dSLs were found to 
be elevated in the plasma of patients affected with metabolic syndrome or diabetes type 2 
(T2D)10-12. Recently, deoxy-ceramide was reported to act as a scaffold lipid facilitating the 
presentation of the lipid antigen for recognition by T-cells. Deoxy-ceramides, due to their 
hydrophobicity, help the lipid antigen to navigate for its presentation by the CD1b receptor13. 
This discovery established a physiological context where dSLs could play a role in innate 
immunity. 
The objective of this study was to reveal factors that contribute to the generation of dSLs in 
wildtype SPT and to gain information about the downstream processing of deoxy-
sphingolipids.  
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FIGURE 1A: Sphingolipid de novo synthesis pathway with L-serine and L-alanine 
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Experimental Procedures 
Cell culture 
HEK293, COS-1, HeLa, HepG2 and NIH/3T3 RAW cells were cultured in DMEM, CHO and 
LYB in Ham F12, JURKAT in RPMI 1640, PC12 in RPMI1640 with 5% horse serum, T84 in 
50% DMEM and 50% Ham-F12, JEG in MEM and JAR in RPMI 1640; all cell lines were 
supplemented with 10% FCS. HL60 cells were cultured in IMDM with 4mM L-Glutamine 
and 20% FCS and THP1 cells in RPMI containing 2mM L-glutamine, 4.5g/L glucose, 1mM 
sodium-pyruvate and 10% FCS. EBV transformed lymphocytes were cultured in RPMI 1640 
supplemented with 15% FCS, 2mM L-glutamine, 1mM sodium-pyruvate, 0.075% sodium-
bicarbonate and 1mM HEPES. One hundred U/ml and 0.1 mg/ml penicillin/streptomycin 
(FisherScientific FSA15-043), respectively were present in all culture media. The cell lines 
were obtained from ATCC and the media from Sigma-Aldrich. THP1 cells were differentiated 
into macrophages using 200nM PMA (in ethanol). 
 
Protein extraction and determination of concentration 
Protein was extracted by re-suspension of the cell pellet in cold lysis buffer (50mM HEPES, 
5mM EDTA and 0.2% Triton-X). After 30min incubation on ice, the extract was centrifuged 
for 5min at 16.000x g at 4°C (Eppendorf). Protein concentration was determined using the 
Bradford Protein Assay (Biorad) according to manufacturer’s instructions. 
 
Analysis of total sphingoid base content and SPT protein expression in primary human 
monocytes 
Monocytes were isolated from human buffy coats and cultured in the presence of RPMI 
containing 10% horse serum for 6 days and were subsequently stimulated with PMA, solvent 
control (DMSO) or were left untreated for 24h or 72h. The culture media was collected for 
amino acid measurement (analysis done at the Functional Genomic Center Zürich, 
Switzerland). The cells were harvested, the protein was extracted and 100ug total protein was 
used for acid-base lipid extraction. Two hundred pmol deuterated internal extraction standards 
(d7-C18SA, d7-C18SO, d5-m17:0) were added to the protein extract prior to extraction. 
Twenty ug total protein was separated using a 12% SDS-PAGE gel, immuno-blotted and 
stained using anit-SPTLC13 (1:2000), anti-SPTLC23 (1:3000) and GAPDH (1:5000, Abnova) 
antibodies. THP1 differentiation status was monitored via the upregulation of CD14 (1:1000, 
Serotec).   
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Fumonisin B1 dependent SPT activity assay  
Fumonisin B1 (Sigma) was added to the medium of exponentially growing cells in a final 
concentration of 13.85uM. As a negative control, myriocin (25uM, Sigma) was added 
together with Fumonisin B1. Twenty-four hours after Fumonisin B1 addition, cells were 
washed twice with cold PBS, harvested and counted (Z2 Coulter Counter, Beckman Coulter). 
Cells were centrifuged (800xg, 5min at 4°C) and pellets were stored at -20°C until lipid 
extraction.  
 
Lipid extraction and hydrolysis 
Total lipids were extracted from cells according to the method of Riley et al.14. The extracts 
were either base -or acid and base hydrolyzed as stated in the text. Lipid extraction, hydrolysis 
and LC-MS analysis was performed as previously described5. The quantified lipids were 
normalized to cell number (per million cells) relative to the internal extraction standard (as 
stated in the text).  
 
Measurement of amino acids 
For analysis of the intracellular amino acids, the internal amino acid standard (beta-amino-
butyrate, Sigma) was added to the cell pellets and included in the lipid extraction procedure 
(acid-base or base-only). Five -hundred ul of the watery upper phase (see under section lipid 
extraction and hydrolysis of Penno et al.5) or 500ul of conditioned media was collected and 
after adding perchloric acid to 0.25M final concentration, the sample was centrifuged at 
16000 x g for 10min at 4°C. The amino acids present in the supernatant were derivatized 
online with ortho-phthaldialdehyde14 containing 0.001% v/v 3-mercaptopropionic acid (OPA-
MPA) in a ratio of 37.5% (supernatant) to 62.5% (OPA-MPA). One minute post 
derivatization, the OPA-amino acids were directly injected and analyzed on a Shimadzu 
HPLC system using an Agilent Zorbax Eclipse AAA column (4.6, 150, 5um) and 
fluorescence detection. Chromatographic conditions were chosen according to the standard 
“Eclipse” analysis protocol (Agilent). 
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Results and discussion 
I. Analysis of the sphingolipid profile and SPT protein expression in different cell lines 
To get an overview of the generation or metabolism of dSLs, we compared the sphingoid base 
profiles of various commonly used cell lines from human, mouse, rat and hamster. The cells 
were cultured for three days, the lipids were extracted and the sphingoid base profile was 
analysed by LC-MS after an acid hydrolysation step (Figure 1B). Hereby the analysed 
sphingoid backbones represent the total amount of sphingolipids or deoxy-sphingolipids 
present in these cells5.  
 
 
FIGURE 1B: Illustration of sphingoid bases after acid-base hydrolysis 
 
Profile of sphingolipid species in various cell lines 
Sphingosine was the major sphingoid base in all cell lines, at highest concentration in T84, 
JEG, JAR and Hela cells. Lower amounts of sphingosine backbones were detected in HEK, 
CHO and COS cells (Figure 1C).  
C16-derived sphingoid bases were detected in the  highest amounts in T84, PC12, JEG and 
JAR cells (Figure 1D). C16-derived sphingoid bases result from the condensation of 
myristoyl-CoA (instead of palmitoyl-CoA) with L-serine, a reaction that is catalysed by the 
SPTLC3 subunit possibly in combination with ssSPTb2,3. The general amount of C16-based 
sphingoid bases did not correlate with the amount of C18 sphingoid bases, indicating that the 
sphingolipid species are formed by distinct pathways.  
Deoxy-sphingolipids accumulated to a different extent in the analysed cell lines. The highest 
amount of dSLs (50pmol/1mio cells) was found in RAW cells, a mouse leukemic macrophage 
cell line. Human embryonic kidney cells (HEK293) also had significant levels (20pmol/1 mio 
cells) in comparison to other cell lines (Figure 1E). Deoxy-sphingolipid levels in these cells 
did not correlate with the total levels of C18 sphingoid bases which are shown as the sum of 
sphingosine and sphinganine (SO+SA) (Figure 1C). This indicates that in RAW and HEK293 
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cells, dSLs are generated due to a specific switch in the activity towards L-alanine, rather than 
as a by-product of the general SPT activity. Differences between the cell lines were also seen 
with respect to the formed dSL species. Deoxy-sphinganine (deoxySA) was the major dSL 
found in most cell lines (Figure 1E). However, in human colonic adenocarcinoma T84 cells 
and human placenta cells (JEG), deoxySO was the predominant dSL (Figure E). The majority 
of serine-based sphingolipids in the cells were found in the sphingosine form whereas the 
alanine-derived metabolites were mostly found in the dihydro-sphingosine form (deoxySA). 
This difference could either stem from the CerS step or the desaturase step in the synthesis 
pathway. Since the analysed sphingolipids were chemically hydrolysed we are not able to 
distinguish between those steps. For that purpose the analysis of the (deoxy-) ceramide 
species is necessary.   
 
C:          D: 
                     
 
E: 
  
FIGURE 1C-E: Total C18- and C16-based sphingoid and deoxy-sphingoid bases in 
different cell lines 
Cells were cultured for 3 days in their respective media (experimental procedures), harvested and 
counted and the lipids were methanol-chloroform extracted. Lipids were acid-base hydrolyzed and the 
resulting sphingoid bases analyzed using LC-MS. Sphingoid bases were quantified relative to an 
internal extraction standard (C17SO) and to 1 mio cells. 
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SPT protein expression pattern  
Second, we compared the expression profile of SPTLC1 and SPTLC2 in the various cell lines 
(Figure 1F). They differed in the expression of both SPT subunits, with high expression of 
SPTLC1 (55kDa) and SPTLC2 (62kDa) in RAW, HEK293, JEG, JAR, COS (among others) 
and low expression in monocyte cell lines like THP1 and HL60 cells. Furthermore, signals 
corresponding to smaller SPT proteins were detected. Using an anti-SPTLC2 antibody3, a 
protein of 32kDa size was detected in almost every cell line analysed (except THP1, JEG, 
CHO and LYB cells). Using an anti-SPTLC1 antibody3, a protein correlating to 25kDa in size 
was detected in COS, HEK293, HL60wt, with the highest expression in T84 cells.  
 
 
FIGURE 1F: Protein expression profile of analysed cell lines 
Protein extracts of different cell lines were separated on a 12% SDS-PAGE gel, immune-blotted and -
stained. Detection was performed using antibodies against SPTLC1, SPTLC23 and GAPDH (Abnova). 
Indicated sizes according to molecular size standard (PageRulerTM, Thermo Scientific). Sizes of 
respective proteins: SPTLC1 55kDa, SPTLC2 62kDa; SPT splice variants, SPTLC1-N162 25kDa, 
SPTLC2-C293 32.6kDa and SPTLC2-N204 24.5kDa; GAPDH 37 kDa. HL 60+/- indicates expression 
of  a functional (+) or non-functional (-) CB2-receptor. 
 
Identification of several SPT splice variants  
A systematic EST (Expressed Sequence Tag) database screen was performed to search for 
potential splice variants of SPT. This revealed several possible splice variants for both SPT 
subunits.  
hSPTLC1-N143, a splice variant of SPTLC1, is composed of the first 143 amino acids of the 
N-terminus.  For SPTLC2, three splice variants were found. hSPTLC2-N162 contains 162 
amino acids of the N-terminus and hSTPLC2-N204, is composed of the N-terminal 204 
amino acids. A third splice variant of SPTLC2, namely hSPTLC2-C293, possesses 293 amino 
acids of the C-terminal end, thereby including the PLP binding motif -the catalytic center of 
the condensation reaction. Previous research in our group discovered that mRNA of these 
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splice variants is expressed in a tissue specific manner and is also detectable on the protein 
level (data not shown). Three of these potential splice variants correlate in size with the 
smaller proteins that were detected in the cell lines (hSPTLC2-C293 32kDa, hSPTLC2-N204 
25kDa and hSPTLC1-N143 25kDa, Figure 1F). However, cloning and individual over-
expression of theses splice variants in HEK293 cells affects neither SPT activity nor cell 
growth (not shown).  
 
II. Monitoring dSL generation during monocyte to macrophage differentiation 
Deoxy-sphingolipids were found at considerable concentrations in macrophages but were 
hardly present in monocyte cell lines like THP1 or HL60 cells (Figure 1E). We therefore set 
out to monitor dSL levels during PMA (phorbol-12-myristate-13-acetate) stimulated 
differentiation of THP1 monocytes into macrophages. After the addition of PMA to cultured 
THP1 cells, they start to differentiate in a time-dependant manner into macrophages. The 
differentiation status can be monitored by the up-regulation of macrophage specific surface 
markers like CD14 or CD1615. To analyze exclusively the de novo generated products of SPT 
during the differentiation period, we used Fumonisin B1, a potent inhibitor of CerS to block 
the downstream pathway (Figure 1A)16. This blockage leads to a time dependant 
accumulation of SPT products that directly correlate with SPT activity. After the addition of 
PMA to cultured THP1 cells (time point 0), FB1 was additionally added after 0, 5, 10, 21, 46, 
71 and 96 hours of PMA supplementation. After 24h of FB1 incubation and hence pathway 
blockage, the cells were harvested, and the lipids were extracted and base hydrolysed, 
enabling only the non-acylated (lyso-) sphingolipids to be included in the analysis. The SPT 
de novo products sphinganine (SA) and deoxy-sphinganine (deoxySA) were analysed by LC-
MS and quantified relative to the synthetic internal standard C17SO.  
Deoxy-sphingolipid generation increased during PMA stimulated differentiation of 
monocytes into macrophages 
During the PMA stimulated differentiation of monocytes into macrophages, no SA was 
generated by SPT upon FB1 inhibition (Figure 2A, Supplementary Figure 1A). In contrast, 21 
hours after PMA addition, SPT started to generate the alanine-derived dSLs (deoxySA and 
deoxySO) in the presence of FB1 (80pmol/1mio cells). The generation of these dSLs 
increased in an almost linear manner during the differentiation process and reached a total of 
600pmol/1mio cells after 96 hours (Figure 2A, Supplementary Figure 1B). Thus, the more the 
monocytes differentiated into the macrophage-like phenotype, the more dSLs were generated. 
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To compare the effect of PMA in another cell line, we chose HEK293 cells as they were also 
able to generate dSLs (Figure 1E). 
 
A:      B: 
   
FIGURE 2A+B: SPT activity in PMA stimulated THP1 cells and HEK293 cells 
THP1 (A) and HEK293 cells (B) were cultured in the presence of 200nM PMA (given at timepoint 0). 
At each indicated time point (0, 5, 10, 21, 46, 71, 96h), FB1 (13.85uM) was added to the cells and 
incubated for 24h, leading to an accumulation of the direct SPT products SA and deoxySA (Figure 
1A). Cells were harvested, and lipids were base extracted allowing the free (non-acylated) sphingoid 
bases to be measured with LC-MS. Sphingoid bases were quantified relative to the internal extraction 
standard (C17SO) and to 1 mio cells. 
 
HEK cells accumulated SA steadily up to 1200 pmol in the first 47 hours of the culture 
period,  but after 70 and 94hours only 200-300pmol of SA was accumulated (Figure 2B, 
Supplementary Figure 1C). HEK293 cells also generated increasing amounts of dSLs during 
this period but to a lesser degree than THP1 cells during differentiation. In THP1 cells, dSL 
levels reached 600pmol in sum (deoxySO+deoxySA), whereas HEK cells accumulated 
40pmol in the late culture phase (Figure 2A+B, Supplementary Figure 1C). Upon FB1 
stimulation, HEK cells produced deoxySA, but deoxySO was not detected in higher amounts 
(Figure 2B). In the presence of FB1, CerS is potently inhibited, thus preventing N-acylation, 
further metabolism by DES, and hence the formation of its downstream products SO or 
deoxySO (Figure 1A). In this context, it is surprising that the alanine-derived downstream 
product deoxySO is being generated during THP1 differentiation in an even higher amount 
than its precursor deoxySA, despite the presence of FB1 (Figure 2A, Supplementary Figure 
1A).  
FB1 is a known activator of PKC17, 18. On the other hand, sphingoid bases like SO and SA, 
that accumulate upon FB1 treatment, were reported to inhibit PKC19. In the presence of PMA, 
THP1 cells, in contrast to HEK cells, failed to accumulate SA upon FB1 stimulation. 
Therefore activation of PKC by FB1 is not influenced by delayed accumulation of SA. Prior 
to the addition of PMA (see timepoint -24h in Supplemental Figure 1A) THP1 cells do 
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accumulate SA upon FB1 stimulation, suggesting that PMA interferes with the FB1-related 
CerS inhibition.  
C:             D: 
  
FIGURE 2C+D: Intracellular amino acid levels in THP1 cells during differentiation (C) 
and in the culture media of HEK293 cells during culture (D) 
Intracellular aminoacid levels were measured in the watery phase that was collected during the process 
of lipid extraction (see experimental procedures). Aminoacids (intracellular or in the culture medium) 
were derivatized using OPA-MPA and analysed by HPLC relative to the internal standard (beta-
aminobutyrate). 
 
We included the measurement of the intracellular amino acids substrates, L-serine and L-
alanine, in THP1 cells in this set-up (Figure 2C) and compared it to the amino acid levels in 
the media during HEK cell culture (Figure 2D) as intracellular levels in HEK293 cells could 
not be measured due to technical problems.  
In THP1 cells we observed an increase in the intracellular L-alanine concentration (0.25 fmol-
0.6 fmol per cell) during the differentiation that correlated with the increased dSL generation 
(Figure 2A+C). At the same time, the intracellular L-serine concentration did not increase 
during the differentiation process and stagnated at 0.1-0.13 fmol per cell (Figure 2C). In HEK 
cells, L-alanine increased in the culture medium, whereas L-serine decreased (Figure 2D). 
Thus, the amino acid levels in the culture media correlated with the generated SA and 
deoxySA in HEK cells. These data suggest that dSLs increase correlates to a general increase 
in alanine.  
 
FB1 increased the generation of deoxySO during PMA stimulated THP1 differentiation  
Analysing the influence of FB1 on deoxySO levels revealed, that in the late culture phase, 
free deoxySO levels in the presence of FB1 were higher, compared to their total cellular 
amount without FB1 treatment (Figure 2E). The levels of the precursor metabolite deoxySA 
were not different when analyzed in these two conditions (Figure 2F). This indicates that FB1 
stimulated deoxySO generation without changes in deoxySA levels. As there is neither 
accumulation of SA throughout the differentiation process (Figure 2A) the apparent 
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contradiction of deoxySO generation in the presence of FB1 might be explained by an 
interference of PMA with FB1 innhibition. This is supported by the observation that prior the 
addition of PMA to THP1 cells (at timepoint -24h), the cells accumulated SA upon FB1 
stimulation (Supplemental Figure 1A). It has been reported that FB1 stimulates dSL 
generation, although the mechanism was not described6. Here, we confirm the increase of dSL 
generation by FB1 in THP1-derived macrophages, with the notion that the increased dSL 
species is deoxySO and not deoxySA, as expected in the presence of FB1.   
 
E:             F: 
   
 
F
FIGURE 2E+F: Deoxy-sphingoid base levels in THP1 cells in the presence and absence of 
FB1 
THP1 cells were grown in the presence of 200nM PMA added at time point 0. At each indicated time 
point (0, 5, 10, 21, 46, 71, 96h) the cells were harvested and the lipids were acid-base hydrolysed 
(aBH) or in the case of FB1 treatment, base-hydrolysed (bH), allowing only the free (non-acylated) 
deoxy-sphingoid bases to be included in the measurement with LC-MS. FB1 (13.85uM) was added to 
the cells 24h prior to harvesting. For example at 46h harvest: FB1 was added 22h after PMA addition 
and further cultured for 24h. Sphingoid bases were quantified relative to the internal extraction 
standard (C17SO) and to 1 mio cells. 
 
 
SPT protein expression profile changed in a controlled manner during differentiation that 
correlated temporally with the increase in dSLs  
Ninety-six hours after PMA stimulation, THP1 monocytes differentiated into macrophages, a 
process that was monitored by the up-regulation of the macrophage surface marker CD14 
(Figure 2G). Analyzing the SPT expression profile of THP1 cells during differentiation 
revealed the up-regulation of both SPT subunits (SPTLC1 -55kDa and SPTLC2 -62kD), 
which was more pronounced for the SPTLC2 subunit (Figure 2G).  
Besides the SPTLC2 subunit, two other SPTLC2 immunoreactive bands with approximate 
molecular weight of 32kDa and 25kDa could be detected. The 25kDa protein expression 
decreased during differentiation whereas the 32kDa protein was stably expressed. The 32kDa 
protein was detected in other cell lines as well, whereas the 25kDa protein was exclusively 
expressed in monocyte cell lines like THP1 or HL60 cells (Figure 1F). However, analyzing 
the peptides corresponding to the two small SPTLC2 proteins, after separation on an SDS-
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PAGE and an in-gel digestion, did not reveal SPTLC2 specific peptides using shotgun mass 
spectrometry analysis (data not shown). Therefore we could not confirm that these small 
proteins are splice variants of the SPTLC2 full length protein.  
The analysis of SPT protein expression profile during PMA stimulated differentiation 
revealed a change in the expression of SPT subunits. The timecourse of SPTLC2 expression 
correlated universely with the timecourse of 25kDa SPTLC2 expression. At the same time, L-
alanine started to accumulate in the cells (Figure 2C) and dSL levels increased (Figure 2A).  
 
 
FIGURE 2G: SPT protein expression in THP1 during differentiation 
Total protein was extracted and separated on a 12% SDS-PAGE. Differentiation status was monitored 
via CD14 (1:1000) up-regulation. SPTLC1 (1:1500) and SPTLC2 (1:1250) antibodies3 were used to 
monitor the expression profile of the SPT subunits and their potential splice variants. Indicated sizes 
according to molecular size standard (PageRulerTM, Thermo Scientific). 
 
 
The generation of deoxySO and the increase in intracellular L-alanine but not the increase in 
deoxySA are dependent on the presence of PMA in THP1 cells 
It has been reported that dSLs increase with the duration of culture6. To investigate whether 
the increased generation of dSLs during THP1 differentiation is due to the differentiation 
status and not caused by any culturing effect, we compared the total amount of dSLs in THP1 
cells in the presence or absence of PMA. The early dSL metabolite deoxySA was not affected 
by the presence of PMA (Figure 3A). In contrast, its downstream metabolite deoxySO was 
generated only in presence of PMA (Figure 3B). Intracellular L-alanine levels also increased 
only upon PMA stimulation whereas intracellular L-serine levels were not affected by the 
PMA treatment (Figure 3E). The presence of PMA lead to increased concentrations of serine-
derived sphingoid bases (SO and SA) compared to non-PMA treated (Figure 3C+D).  
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A:               B: 
       
C:       D: 
         
 
E:       F: 
     
FIGURE 3: Effect of PMA on the sphingolipid and intracellular amino acid profile  
THP1 (A-D) and HEK293 (F) cells were cultured either in the presence or absence of 200nM PMA 
(added at time point 0). After 5, 10, 21, 46, 71 and 96 hours, the cells were harvested, and the lipids 
were extracted, acid-base hydrolysed and analysed with LC-MS. Resulting sphingoid bases were 
quantified relative to the respective internal standard (THP1 cells C17SO, HEK293 d7 SO)  and per 1 
mio cells. (E) Intracellular aminoacid levels in THP1 cells were measured in the watery phase that was 
collected during the process of lipid extraction (see experimental procedures). Intracellular aminoacids 
were analysed by HPLC relative to the internal standard beta-aminobutyrate. 
 
 
In HEK293 cells PMA had an opposing effect, as it inhibited deoxySA and deoxySO 
generation during culture (Figure 3F). As the serine-derived sphingoid bases were not affected 
by PMA during HEK cell culture (not shown), the inhibition effect of PMA was specific for 
the alanine-derived sphingoid bases. PMA belongs to the family of phorbolesters and is a 
potent direct activator of cPKCs and nPKCs 20-22. In contrast to diacyglycerol, which only 
transiently activates PKC, PMA stimulates PKC irreversibly. It is well known that PKC 
isozymes can have unique and sometimes opposing roles in signalling or disease states23, 24. It 
has even been reported that the same isozyme can lead to ambiguous responses in the same 
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cell line, depending on the context of the stimuli25. This could explain the different responses 
of the THP1 and HEK293 cells to the PMA treatment.  In THP1 cells we observed a PMA 
dependent increase of deoxySO, while deoxySA levels were unchanged. This could be 
explained by the activation of SPT and its downstream enzymes (CerS and DES) by PMA via 
PKC, that would result in a rapid metabolism of deoxySA to deoxySO. On the other hand, 
PMA could inhibit the degradation of deoxySO.  
 
The increased generation of dSLs during monocyte to macrophage differentiation was 
confirmed in primary human macrophages 
In line with the results reported above on dSL formation, dSL levels also increased in primary 
human monocytes during differentiation into macrophages (Figure 4A). Likewise, the major 
dSL metabolite was deoxySO (90pmol/mg protein) compared to deoxySA (58pmol/mg 
protein). The total SL content was also increased in primary human macrophages during 
differentiation (Figure 4A). 
 
A:       B: 
    
 
 
C:       D: 
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E: 
 
 
FIGURE 4: Sphingolipid profile in human macrophages 
Monocytes were isolated from human buffy coats and cultured for 9 days for differentiation into 
macrophages. At day 6, no treatment (A), PMA or solvent (B-E) was added to the cells. Cells were 
harvested at day 0, 7 and 9, lipids were extracted and acid-base hydrolysed, and the total SL and dSL 
content was measured using LC-MS relative to the internal standard (d5 deoxymethyl-sphinganine) 
and 1 mg total protein. 
 
To control for a possible PMA-related effect, at day 6 PMA and DMSO (solvent) were added 
to the cells. Due to limited material no aliquot was harvested at day 6 at the time of treatment. 
Therefore the SL and dSL levels at day 6 are not known, hampering the determination of the 
exact increase at day 7 and 9 (Figure 4B-E). Nevertheless, at day 7 and 9, the deoxySO 
content in PMA treated cells was slightly higher than in untreated cells (Figure 4B) whereas 
total SO content was faintly decreased (Figure 4D). Besides, aminoacids in the culture 
medium were analysed. We observed an increase in L-alanine during the differentiation that 
was accompanied by a decrease in L-serine (Figure 4F).  
 
       
FIGURE 4F: Aminoacid profile in the media measured during culture of human 
macrophages  
Aminoacid measurement was carried out at the Functional Genomic Center Zürich 
http://www.fgcz.ch/supportmodes/proteinservice/aminoacidanalysis 
 
Chapter 3 
 
 92
We did not measure the intracellular amino acid levels, and hence do not know if the alanine 
concentration in the cells followed the same pattern and increased during the differentiation. 
In this context we also detected changes of other amino acids in the culture media during 
differentiation (Figure 4F). Analysing the protein expression during differentiation confirmed 
the up-regulation of SPTLC1 as well as SPTLC2 in primary monocyte-derived macrophages 
(Figure 4G). Next to the full length SPTLC proteins, smaller anti-SPTLC1 and anti-SPTLC2 
35kDa bands were detected. The expression of the smaller SPTLC1 but not of the smaller 
SPTLC2 protein was up-regulated during the differentiation (Figure 4G). 
 
 
FIGURE 4G: Expression profile of SPT proteins in human macrophages 
Total protein was extracted and separated on a 12% SDS-PAGE. SPTLC1 (1:1500) and SPTLC2 
(1:1250) antibodies3 were used to monitor the expression profile of the SPT subunits; GAPDH 
(1:5000, Abnova) was used as the loading control. Indicated sizes according to molecular size standard 
(PageRulerTM, Thermo Scientific) 
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Conclusions and outlook 
We showed that dSLs generation is increased during PMA driven THP1 differentiation, an 
event that is accompanied by the intracellular accumulation of L-alanine. The generation of 
deoxySO was dependent on the presence of PMA, and was paradoxically increased by the 
upstream CerS inhibitor FB1. The PMA/FB1 dependant deoxySO generation was specific to 
THP1 macrophages. In HEK cells we rather observe the opposite effect, namely inhibited dSL 
generation. Phorbolesters like PMA as well as Fumonisin B1 are strong activators of PKC 
that both interact with the diacyglycerol binding site of PKC17, 18. By contrast, sphingoid 
bases like SO and SA, were reported to inhibit PKC19. Increased activation of  PKC isoforms 
is involved in many diseases 26-34 including diabetic complications, like diabetic neuropathy35, 
36. In this context it is interesting to note that dSLs were shown to be elevated in the metabolic 
syndrome with the later risk of T2D11, 12. Whether PKC activation is involved in the signalling 
events that contribute to the generation of dSLs in general, or specifically in the monocyte-
macrophage context, needs to be addressed in detail by using specific inhibitors/activators of 
the various PKC isoforms.  
We confirmed increased dSL generation in human primary monocyte-derived macrophages. 
Interestingly this was independent of PMA stimulation. This further establishes a 
physiological relevance for dSLs. The question why dSL are generated during macrophage 
maturation is not clear yet.  
Monocyte recruitment into inflamed vessels is believed to promote atherosclerosis. A 
functional link between sphingolipids and cholesterol efflux of macrophages was described by 
Tamehiro et al. He and his colleagues identified the SPTLC1 subunit as a binding partner of 
ABCA1 in THP1 monocyte-macrophages as well as in mouse liver. Binding of ABCA1 to 
SPTLC1 was found to inhibit cholesterol efflux activity, thereby maximizing the cellular 
cholesterol in cells with a demand in membrane synthesis37. Moreover Par3, a scaffolding 
factor that recruits signaling molecules into multiprotein complexes, was identified as another 
binding partner of SPTLC1 in THP1-derived macrophages. The knock-down of Par3 or 
SPTLC1 both decreased SPT activity and chemotaxis-induced migration of THP1 
monocytes38. If dSLs are involved in these events needs to be addressed in future 
experiments.  
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A:       B: 
  
C:       D: 
              
SUPPLEMENTARY FIGURE 1: Myriocin controls for FB1 treated cells  
THP1 cells (A+B) and HEK293 cells (C+D) were grown in presence of 200nM PMA and 
supplemented with 13.85mM FB1 that blocks CerS and leads to an accumulation of SPT products. 
PMA was added at time point 0, FB1 was given at indicated time points and incubated for another 
24h. Note: at time point -24h in THP1 cells no PMA was present. To control for an FB1 related 
sphingoid base accumulation, myriocin that blocks SPT, was added together with FB1 in a separate 
set-up. 
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General Conclusions 
 
Canonical SPT activity: The enzymatic reaction and the influence of the metabolic 
context 
In chapter 1 we described a novel HSAN I-causing mutation (A182P) in the SPTLC2 subunit.  
SPT activity of this mutant was analyzed in transfected HEK293 cells in a cell-free assay and 
in living cells using metabolic labeling. The A182P mutation showed a decreased activity 
with L-serine in cell-free conditions although the cell-based metabolic labeling assay revealed 
no differences in the de novo formation of sphingolipids in mutant-expressing cells compared 
to wt cells (chapter 1, Figure 4A+C). We therefore assumed that SPT activity within the cells 
is generally reduced due to metabolic feedback inhibition when enough sphingolipids can be 
provided from external sources (serum or lipoproteins from medium). In these conditions the 
activity of the mutant SPT might be nevertheless sufficient to provide enough de novo 
generated sphingolipids although the Vmax of the mutant seems to be reduced as shown in 
the cell-free assay (chapter 1, Figure 4A).  A recent report supports this concept by 
demonstrating that SPT activity in cultured cells is largely inhibited under normal medium 
conditions. This inhibitory effect is probably mediated by ORMDL proteins and yet unknown 
additional factors which seem to be present in the serum of the culture media1.  
 
Deoxy-sphingolipid generation: Different mechanisms can lead to the same result 
In this report we showed for the first time that dSL formation in a cell-free environment is 
increased in SPT with specific mutations compared to the wt enzyme. This indicates that 
dSLs are generated due to a structural impact of these mutations on the enzyme resulting in a 
decreased activity with serine and an increased activity with alanine. The new A182P 
mutation showed, like most HSAN I mutations, a reduced canonical activity and resulted 
additionally in increased dSL generation in isolated proteins and also in living cells (Figure 
1A-C). This was not observed for some other HSAN I mutations. Comparing different SPT 
HSAN I mutants revealed that not all of them exhibit activity with alanine in a cell-free 
environment (Figure 1B). Analyzing activity in isolated proteins, only the here described 
SPTLC2-A182P, -S384F, and to a minor extent -I504F resulted in a direct formation of dSLs, 
whereas SPTLC2-G382V, -T409M and V359M along with two analyzed SPTLC1-mutants, -
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C133W and -S331F, did not show formation of dSLs in isolated proteins (Figure 1B+chapter 
2, Figure 7A). 
 
A:      B: 
            
C: 
 
FIGURE 1: Comparison of SPT activity in HSAN I mutants in cell-free conditions  
SPT activity was analyzed in isolated protein of HEK293 cells which were stably transfected with 
vector control (pcDNA3.1), wildtype (SPTLC2), SPTLC2 (A182P, G382V, V359M, I504F, T409M) 
and SPTLC1 (C133W, S331F) mutations that are causing HSAN I.  
The activity was determined in the presence of (A) L-serine or (B) L-alanine. (C) Free (non-acylated) 
deoxySA that was generated in the cells during culture. Sphingoid bases (after base extraction) were 
quantified relative to internal extraction standards (d7SO and d7SA) and 1mg of total protein. 
 
 
However, all HSAN I mutations which were also genetically confirmed were associated with 
an increased dSL formation in transfected cells (Figure 1C)2-6. Elevated dSL levels were also 
confirmed in available plasma samples of HSAN I patients2-6. This indicates that dSL 
generation can be based on different mechanisms. Those mutants that show a significant 
activity with alanine in cell-free conditions probably directly affect the SPT structure, whereas 
those which fail to have this effect, but increase dSL formation in living cells might require 
additional cellular factors to metabolize alanine. Furthermore, a phosphorylation site (S384) 
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in SPTLC2 that has been identified in a global screen7, was shown to be involved in 
regulating the activity of SPT with L-serine and L-alanine, respectively. We showed that 
mimicking a permanently phosphorylated serine384 (S384D) resulted in a robust increase in 
dSL generation in isolated proteins and in living cells (chapter 2, Figure 4B+5A). 
Remarkably, a very similar S384E mutation did not show this effect, indicating that dSL 
formation by the S384D mutation is specific and not simply caused by an arbitrary aminoacid 
exchange at residue 384. In that context we also reported a second novel HSAN I mutation 
(S384F) that resides at the very same position and results in the same activity shift as was 
observed for the S384D mutant. We therefore speculated that either phosphorylation or the 
exchange of the S384 with a bulky amino acid like phenylalanine induces a structural change 
in SPT which leads to the observed shift in activity. However, this hypothesis needs to be 
further proven by identifying the kinase which is responsible for the phosphorylation of 
SPTLC2. As a consequence of our findings an activation of this kinase should also result in 
increased dSL formation.  
Those HSAN I mutations (SPTLC2-G382V; T409M; V359M; SPTLC1 -C133W;-S331F) that 
do form dSLs in cellular but not in cell-free conditions probably have a different mechanism 
to generate dSLs. These HSAN I mutations possibly affect the binding or activity of a factor 
which might co-regulate dSL formation. In addition, factors which regulate the cellular amino 
acid levels could also be directly or indirectly involved in regulating the dSLs. It can be 
speculated that SPT itself might also influence amino acid synthesis or transportation. This 
assumes that sphingolipid and amino acid synthesis (e.g. serine and alanine) are functionally 
connected. The previously reported Serinc proteins might provide this missing link. Serinc 
was reported to connect SPT with PGDH, the first enzyme in the serine synthesis pathway8. A 
more indirect link between these two pathways was reported in yeast, where sphingolipid 
synthesis increased upon amino acid starvation, which is first sensed by the Npr2/Npr3 
complex9 and results in the phosphorylation of ORM1 via the TORC1 downstream effector 
kinase Npr110. The increase in complex sphingolipids was suggested to stimulate the nutrient 
scavenging general amino acid Gap1 permease activity at the plasma membrane as a response 
to starvation11. To investigate this in more detail, future experiments need to analyze the 
composition of the mammalian SPT complex, especially comparing wt and HSAN I mutants. 
Another difference we observed between HSAN I mutants and phosphorylation mimicking 
mutants was the type of generated deoxy-ceramides. We showed in previous work that dSLs 
in HSAN I cells are predominantly present as non-acylated sphingoid bases12, whereas dSLs 
formed by the wt enzyme13 or in the phospho-mutant S384D were mostly found in their 
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acylated form as deoxy-(dihydro)-ceramide (chapter 2, Figure 5D). This suggests that the 
HSAN I mutations have an inhibitory effect on the activity of ceramide synthase (CerS). Free 
sphingoid bases but not the acylated forms, were shown to inhibit PKC14, 15. Therefore, free 
deoxy-sphingoid bases which are generated by the HSAN I mutants might induce a different 
signaling pathway via the inhibition of PKC and consequent downstream signaling events.  
 
Figure 2 shows a structural model with the positions of all reported SPTLC2 HSAN I 
mutations and the here characterized phospho-mutations in S. multivorum (PDB: 3A2B). 
According to this structure, one can speculate that the proximity to the PLP-binding motif 
(around Lys379) and thus the interference with the binding pocket for the amino acid 
substrate might influence the binding of the canonical substrate L-serine. In that sense, 
Thr409, Gly382 (corresponding HSAN I mutations: T409M, G382V) are pointing away from 
the binding pocket and have probably no impact on the amino acid substrate binding. These 
mutants did neither generate dSLs in cell-free conditions, whereas Ser384 and Ala182, which 
are pointing towards the binding pocket, show robust dSL formation also in the absence of 
living cells. However, Ile504 (HSAN I mutation: I504F) is located far outside of the PLP 
binding region but showed nevertheless a slight activity with alanine in isolated proteins. As 
S384D and S384E show a difference when analyzed in cell-free conditions our results point 
out that not only the position but also the nature of the amino acid change are important. A 
bulky residue like phenylalanine in combination with the right position might lead to changed 
substrate specificity and thus to dSL generation in isolated proteins. 
 
FIGURE 2: Structural modeling of SPTLC2-HSAN I-causing mutations in 
Sphingobacterium multivorum  
The sequence of the mammalian SPTLC2 subunit was modeled into the protein structure of S. 
multivorum (PDB:3A2B) using SWISS-MODEL (http://swissmodel.expasy.org). The results are 
illustrated using USCF Chimera 1.6.2. Both phosphosites (Ser384 and Tyr387) are shown in orange 
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and the Schiff-base forming Lys379 (catalytic center) is shown in red. All sites that are HSAN I-
causing mutations in SPTLC2 are shown in yellow (Thr 409, T409M; Ala182, A182P; Ile504, I504F; 
Ser384, S384F) 
 
HSAN I-a product of mutations in five different genes and more to come 
The clinical phenotype of HSAN I can be very heterogeneous, ranging even within the same 
family from a very mild phenotype with primarily allodynia and late onset  to very severe 
forms with congenital onset , progressive degeneration of sensory and autonomic neurons and 
severe motor involvement16 17. This heterogeneity argues for the role of modulating factors 
which might act on top of the identified mutations. Moreover, HSAN I is genetically 
heterogeneous. Five genes (SPTLC1, SPTLC2, ATL1, RAB7 and DNMTI) have been described 
so far to be mutated and cause the HSAN I phenotypes. RAB7 is involved in vesicular 
transport; Atlastin-1 is a dynamin related GTPase that functions in the ER tubular network, 
and DNMT1 is involved in DNA methylation. ER stress and axonal transport are two 
common pathways that are shared by these genes16. However, there is a pool of patients with 
HSAN I-like symptoms but no mutations in these candidate genes. New gene sequencing 
methods (e.g. whole exome sequencing) will allow the identification of new disease-causing 
genes in these patients and might finally help to unravel a shared pathomechanism which 
underlies all these different mutations.  
 
Deoxy-sphingolipids in macrophages  
 In chapter 3 we reported that dSLs are generated during PMA-induced THP1 differentiation 
into macrophages. We confirmed this observation in differentiating primary monocytes. The 
question of why dSLs are increased in the maturation of monocytes to macrophages and 
whether they play a causal role in this process is not clear. Macrophages play a key role in the 
context of inflammation for example in atherosclerosis or obesity. Great effort is being made 
to understand how an increased body fat content results in chronic inflammation which also 
underlies the pathology of these disorders. Lately, it has been reported that endotoxins 
activate sphingolipid de novo synthesis via LPS induced nuclear factor kappa B (NFκB) 
mediated up-regulation of SPTLC2 mRNA (but not SPTLC1) in RAW cells and peritoneal 
macrophages18. NFκB directly binds to the SPTLC2 promoter leading to increased expression 
of the SPTLC2 transcript and protein, thereby activating sphingolipid de novo synthesis 
which results in increased ceramide levels. It was shown that palmitate activates SPT activity 
and hence ceramide generation19. Holland et al. found that not only palmitate but also other 
free fatty acids (stearate, arachidate and lignocerate) can induce de novo ceramide generation 
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via interaction with the TLR4 receptor. Moreover, they found that LPS and to an even higher 
extent palmitate induced the transcription of enzymes involved in sphingolipid de novo 
synthesis (SPTLC2, CerS1, -2 and -6 and DES1) via the IKKβ signaling complex20. It is 
known that TLR4 signaling increases ceramide levels by activating acid sphingomyelinase18. 
Whether increased ceramide levels (de novo or salvage) lead to more pronounced 
inflammation is currently under debate. Schwartz et al. reported that palmitate or saturated 
fatty acids (SFA) increase IL-6 and IL-8 production in human THP1 cells as well as in 
primary monocytes21. The here proposed mechanism was that de novo generated ceramides 
impact on PKCζ, thereby activating MAPK which results in increased inflammation. 
Moreover, Schilling et al. reported that LPS and palmitate synergistically induce de novo 
ceramide synthesis in mouse macrophages that require TLR4 signaling via myD88 and TRIF, 
but this is independent of NFκB and MAP kinase activation22. These macrophages released 
TNFα and IL-1β after stimulation with LPS and this increase was enhanced with 
supplementation of palmitate. Notably, in mouse macrophages palmitate alone could not 
induce de novo ceramide formation and cytokine release. Schwartz et al. also reported 
differences in signaling responses in mouse and human monocytes/macrophages21. In 
contrast, Holland et al. reported that cytokine release upon SFA-TLR4 interaction was 
independent of de novo synthesized ceramide in mice and rats as well as in cultured 
macrophages20.  
In our own experiments we found that the supplementation of palmitate leads to increased 
SPT activity and enhanced generation of sphingolipids and dSLs in cultured cells (data not 
shown). Moreover, we found in several clinical studies that triglycerides are directly and 
significantly correlated with dSL levels in the plasma of patients with metabolic disorders23. It 
will therefore be interesting to explore whether dSLs are increased in LPS or palmitate 
stimulated macrophages and whether they also play a role in the described signaling 
processes.  
 
Deoxy-sphingolipid de novo pathway in macrophages 
We also reported in chapter 3 that both PMA, the stimulus for THP1 differentiation, and FB1, 
an inhibitor of ceramide synthase, influence the generation of deoxySO - the downstream 
product of deoxySA. The formed deoxySA is acylated to deoxy-dihydro-ceramide13. 
Therefore dSLs are generally found in their acylated forms - primarily conjugated  to a C16, 
C24:1 and C24 fatty-acids 13. We described the generation of the unsaturated downstream 
metabolite (m18:1 or deoxySO), suggesting that deoxy-dihydro-ceramide is a substrate for the 
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desaturase DES1/2. Paradoxically, deoxySO appears under conditions where FB1 was used to 
block the synthesis pathway at the step of CerS and hence upstream of DES. The levels of 
non-acylated deoxySO relative to total deoxySO bases were higher in FB1 treated THP1 cells 
compared to untreated cells. We propose two explanations for this phenomenon. Along with 
the generation of deoxySO in the presence of FB1, there is a lack of SA accumulation 
(chapter 3, Figure 2A). Therefore, the inhibitory potential of FB1 on CerS could be impaired. 
We observed SA accumulation prior to the addition of PMA for starting the differentiation 
(chapter 3, Supplemental Figure 1A). Thus, PMA could interfere with the FB1 related CerS 
inhibition. Whether there is interference and how this takes place needs to be addressed by 
future experiments. One may also speculate that dSLs follow a different metabolic pathway in 
which the desaturase is not dependent on prior acylation to a deoxy-dihydro-ceramide 
molecule (Figure 3). In this case we would expect that the desaturase could introduce the 
double-bond directly into the free deoxySA which is, however, not possible for sphinganine24. 
Hence, it has to be investigated if the majority of deoxySA/deoxySO is present as a free base 
or in its N-acyl form. In our experimental setup the information on the deoxy-ceramide 
species is lost due to the chemical hydrolysis of the N-acyls prior to the MS analysis. Future 
experiments have to analyze the individual deoxy-ceramide species and their metabolism and 
dynamics during monocyte to macrophage differentiation.  
The major difference between PMA and non-PMA treated THP1cells was seen in the 
deoxySO levels. DeoxySO formation during differentiation was dependent on the presence of 
PMA. However, the addition of FB1 further enhanced deoxySO levels. FB1 and PMA are 
both activators of certain PKC sub-isoforms (PKCα, βII, δ, ε)25. Here, FB1 could play a dual 
role by acting as a direct activator of PKC via the diacylglycerol binding pocket26, 27 but also 
causing the accumulation of SA and SO , which act as PKC inhibitors14, 15. However, due to 
unknown reasons, differentiating THP1 cells did not show any accumulation of SA (neither 
SO) upon FB1 treatment and would therefore lack this delayed inhibition of PKC. It will be 
interesting to test the effect of deoxy-sphingoid bases on the PKC subtypes, as they 
structurally resemble FB1. FB1 can be considered as a 1-deoxy-sphingolipid-analogue, but in 
contrast to deoxy-sphingoid bases, it is built on a polyketid backbone28, 29. The addition of 
FB1 was shown to also increase dSL generation in other cell lines, although the underlying 
mechanism is not understood13.  
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FIGURE 3: Proposed mechanism for deoxySO generation in the presence of PMA and 
FB1 in THP1-derived macrophages  
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Outlook 
In summary this work investigated several factors that are involved in the generation and the 
metabolism of dSLs. Based on our results we suggest that phosphorylation of SPTLC2 at 
S384 leads to a shift in the amino acid substrate preference of SPT. We propose that 
phosphorylation acts as a molecular switch which directly affects SPT structure and results in 
increased dSL. However, future work needs to prove this hypothesis by identifying the 
responsible SPTLC2 kinase and also the regulatory stimuli that provoke SPT phosphorylation. 
Comparing individual HSAN I mutations, we observed differences of SPT activity when 
analyzed in isolated proteins and in living cells. In contrast to wildtype SPT and the majority 
of HSAN I mutants, only some HSAN I mutants produced dSL in the presence of alanine in 
cell-free conditions. However, the expression of almost every HSAN I mutant in cells resulted 
in increased dSLs formation, even those variants which did not form dSLs in cell-free 
conditions. We therefore postulate that dSLs can be formed by different mechanisms. To 
further explain these differences it is important to gain better insight into the regulation of 
sphingolipid de novo synthesis and the factors which are involved in this regulation. The 
systematic comparison of the various HSAN I mutations in terms of the formation of supra-
molecular SPT complexes with other proteins and their product spectrum might be a valuable 
tool to address this issue. Since we also see differences in the deoxy-ceramide species 
between HSAN I mutants (primarily as free sphingoid bases) and phospho-mutants (primarily 
N-acylated) it will be interesting to investigate a potential inhibitory effect of the HSAN I 
mutants on CerS in more detail. Therefore it is also essential to investigate the formed deoxy-
sphingolipid species in more detail, in particular the presence and length of the conjugated N-
acyl chain. Each of these dSL-metabolites could, in principle, drive a different signaling event 
that might explain the observed controversial responses of the dSLs, like being toxic to 
cultured DRGs but being generated during macrophage maturation and prolonged culture of 
cells.  
Whether there is a physiological relevance of dSLs still needs to be determined. We found 
dSL generation coordinated with increased intracellular L-alanine levels and a drastic change 
in SPT expression pattern during the monocyte to macrophage differentiation. As dSL 
resemble structurally FB1, we speculated that they can play a role in signaling processes. 
Further experiments need to address this issue as well as the context in which the dSL 
signaling takes place. 
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We showed a close metabolic link between the sphingolipid and amino acid synthesis 
pathways. To gain more information about this interconnectivity, future experiments should 
address the regulation of the amino acid supply. As Serinc-proteins have been reported to 
provide a platform for the facilitated shuttling of amino acids by membrane proteins, it could 
be investigated if there are differences in the amino acid metabolism between HSAN I 
mutants and wildtype SPT.  
Increased deoxy-sphingolipids are a hallmark for HSAN I and there is growing evidence that 
they also play a role in the pathogenesis of other neuropathies. However, besides the 
observation that dSLs are toxic to DRGs in culture30, it is not known how and at which step 
they are involved in the underlying pathomechanism of nerve destruction. Thus, future work 
needs to investigate the underlying pathomechanism of dSLs in neurotoxicity. ORM proteins 
have been identified as regulators of SPT activity thereby potentially linking SPT with other 
diseases like asthma or Alzheimer’s, where ORM proteins were found to play a role. It will be 
of interest to investigate whether dSLs also play a role in the context of these diseases. 
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